Aging is the main risk factor for many chronic degenerative diseases and cancer. Increased senescent cell burden in various tissues is a major contributor to aging and age-related diseases. Recently, a new class of drugs termed senolytics were demonstrated to extending healthspan, reducing frailty and improving stem cell function in multiple murine models of aging. To identify novel and more optimal senotherapeutic drugs and combinations, we established a senescence associated β-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells. We used primary Ercc1 −/− murine embryonic fibroblasts with reduced DNA repair capacity, which senesce rapidly if grown at atmospheric oxygen. This platform was used to screen a small library of compounds that regulate autophagy, identifying two inhibitors of the HSP90 chaperone family as having significant senolytic activity in mouse and human cells. Treatment of Ercc1 −/∆ mice, a mouse model of a human progeroid syndrome, with the HSP90 inhibitor 17-DMAG extended healthspan, delayed the onset of several age-related symptoms and reduced p16INK4a expression. These results demonstrate the utility of our screening platform to identify senotherapeutic agents as well as identified HSP90 inhibitors as a promising new class of senolytic drugs.
P53
January 4, 2020
TELOMERE SHORTENING & PREMATURE AGING
January 7, 2020Hsp90 (heat shock protein 90) is a chaperone protein that assists other proteins to fold properly, stabilizes proteins against heat stress, and aids in protein degradation. It also stabilizes a number of proteins required for tumor growth, which is why Hsp90 inhibitors are investigated as anti-cancer drugs.
Heat shock proteins, as a class, are among the most highly expressed cellular proteins across all species.[3] As their name implies, heat shock proteins protect cells when stressed by elevated temperatures. They account for 1–2% of total protein in unstressed cells. However, when cells are heated, the fraction of heat shock proteins increases to 4–6% of cellular proteins.[4]
Heat shock protein 90 (Hsp90) is one of the most common of the heat-related proteins. The “90” comes from the fact that it weighs roughly 90 kiloDaltons. A 90 kDa protein is considered fairly large for a non-fibrous protein. Hsp90 is found in bacteria and all branches of eukarya, but it is apparently absent in archaea.[5] Whereas cytoplasmic Hsp90 is essential for viability under all conditions in eukaryotes, the bacterial homologue HtpG is dispensable under non-heat stress conditions.[6]
This protein was first isolated by extracting proteins from cells stressed by heating, dehydrating or by other means, all of which caused the cell’s proteins to begin to denature.[7] However it was later discovered that Hsp90 also has essential functions in unstressed cells. -wiki
SCIENTIFIC STUDIES
- Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
- Inhibiting the Hsp90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
- Inhibiting Hsp90 to treat cancer: a strategy in evolution
- Molecular simulation of HER2/neu degradation by inhibiting HSP90
- Inhibiting the Hsp90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease
- Black tea polyphenols induce human leukemic cell cycle arrest by inhibiting Akt signaling: Possible involvement of Hsp90, Wnt/β‐catenin signaling and FOXO1
- Microparticles from patients with the acute coronary syndrome impair vasodilatation by inhibiting the Akt/eNOS-Hsp90 signaling pathway
- Cks1 proteasomal degradation is induced by inhibiting Hsp90-mediated chaperoning in cancer cells
- Inhibiting the molecular evolution of cancer through HSP90
- A chemical compound inhibiting the Aha1–Hsp90 chaperone complex
- Hsp90 is a novel target molecule of CDDO-Me in inhibiting proliferation of ovarian cancer cells
- Inhibiting heat shock protein 90 (Hsp90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice
- Inhibiting Hsp90 prevents the induction of myeloid-derived suppressor cells by melanoma cells
- 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways
- Uncaria rhynchophylla Ameliorates Parkinson’s Disease by Inhibiting Hsp90 Expression: Insights from Quantitative Proteomics
- Targeting Hsp90-Cdc37: a promising therapeutic strategy by inhibiting Hsp90 chaperone function
- Combination Immunotherapy of Melanoma by inhibiting Hsp90 and targeting its client proteins.(TUM7P. 934)
- Influence of co-inhibiting mTORC2 and Hsp90 on proliferation apoptosis of multiple myeloma cells
- Hsp90 inhibiting anti-cancer therapeutics enhance bone loss by increasing osteoclast formation: Mechanism of action.
- Abstract# 1854: Superoxide-dependent hepatotoxicity of the Hsp90 inhibiting anticancer drugs geldanamycin and its two derivatives
- Development of Small Molecules Blocking Glucose Transporter Or Inhibiting Hsp90 for the Therapy of Cancer
- Gambogic acid attenuates liver fibrosis by inhibiting the PI3K/AKT and MAPK signaling pathways via inhibiting HSP90
- Ritonavir inhibits breast cancer cell proliferation, in part, by inhibiting Hsp90 function and Akt phosphorylation
- The effect of curcumin on bortezomib by inhibiting Hsp90 of myeloma MM1. R
- Diosgenin suppressed LPS-induced inflammation through inhibiting Hsp90 induced phosphorylation of NF-κb p65
- Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer
- Inhibiting protein-protein interactions in Hsp90 dimerization as a novel approach for targeting cancer
- Characterization of celastrol to inhibit Hsp90 and cdc37 interaction
- Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase
- Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery
- Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin
- Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells
- Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
- Hsp90 blockers inhibit adipocyte differentiation and fat mass accumulation
- Cyclic lipopeptide antibiotics bind to the N-terminal domain of the prokaryotic Hsp90 to inhibit the chaperone activity
- New, Non‐quinone Fluorogeldanamycin Derivatives Strongly Inhibit Hsp90
- Ca2+/S100 proteins inhibit the interaction of FKBP38 with Bcl-2 and Hsp90
- 2D-QSAR of purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells
- Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug …
- Single-walled carbon nanotubes (SWCNTs) inhibit heat shock protein 90 (Hsp90) signaling in human lung fibroblasts and keratinocytes
- Sarqaquinoic acid and related synthetic naphthoquinones inhibit the function of Hsp90
- Deguelin analogues, L80 and SH-1242, inhibit Hsp90 activity and exert potent anticancer efficacy with limited toxicities in non-small cell lung cancer (NSCLC)
- Abstract B80: Hsp90 inhibitor SNX‐2112 and prodrug SNX‐5422 (PF‐04929113) inhibit key signal pathways Akt, Src and STAT3 and reactivate tumor suppressor …http://mct.aacrjournals.org/
content/8/12_Supplement/B80. short - Hsp90 inhibition decreases mitochondrial protein turnover
- Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress
- Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition
- Inhibition of Hsp90: a multitarget approach to radiosensitization
- Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IκB kinase (IKK)
- Hsp90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer …
- Hsp90 inhibition: two-pronged exploitation of cancer dependencies
- 17 AAG for Hsp90 inhibition in cancer-from bench to bedside
- Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation
- Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses
- Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response
- Hsp90 modulates actin dynamics: inhibition of Hsp90 leads to decreased cell motility and impairs invasion
- … reticulum vacuolization and valosin-containing protein relocalization result from simultaneous Hsp90 inhibition by geldanamycin and proteasome inhibition by …
- To fold or not to fold: modulation and consequences of Hsp90 inhibition
- Mechanistic studies on Hsp90 inhibition by ansamycin derivatives
- ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition
- Inhibition of Hsp90 in Trypanosoma cruzi induces a stress response but no stage differentiation
- Hsp90 Inhibition with Resorcylic Acid Lactones (RALs)
- 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition
- Targeting HSF1 sensitizes cancer cells to Hsp90 inhibition
- Combined EGFR/MET or EGFR/Hsp90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET
- Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis
- Hsp90 inhibition protects against inherited retinal degeneration
- FGFR3 translocations in bladder cancer: differential sensitivity to Hsp90 inhibition based on drug metabolism
- Hsp90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis
- Targeting multiple signal transduction pathways through inhibition of Hsp90
- Inhibition of Hsp90 molecular chaperones: moving into the clinic
- Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation
- Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo
- Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition
- Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic …
- Heat-induced Oligomerization of the Molecular Chaperone Hsp90 INHIBITION BY ATP AND GELDANAMYCIN AND ACTIVATION BY TRANSITION METAL …
- Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
- Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in …
- Inhibition of Hsp90: a new strategy for inhibiting protein kinases
- Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells
- Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the …
- Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
- Hsp90 inhibition: Elimination of shock and stress
- Inhibition of MDM2 by Hsp90 contributes to mutant p53 stabilization
- Inhibition of N-terminal ATPase on Hsp90 attenuates colitis through enhanced Treg function
- Inhibition of Hsp90 compromises the DNA damage response to radiation
- Hsp90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
- Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP
- Inhibition of ALK, PI3K/MEK, and Hsp90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene
- Protein kinase CK2 protects multiple myeloma cells from ER stress–induced apoptosis and from the cytotoxic effect of Hsp90 inhibition through regulation of the …
- Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma
- Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
- Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma
- Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
- Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic …
- Hsp90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways
- Identification of a new scaffold for Hsp90 C-terminal inhibition
- Hsp90 inhibition protects against biomechanically induced osteoarthritis in rats
- Therapeutic potential of Hsp90 inhibition for neurofibromatosis type 2
- Hsp90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy
- Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis
- Induction of premature senescence by Hsp90 inhibition in small cell lung cancer
- Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis
- Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
- Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-
demethoxygeldanamycin - Efficient synthesis of a novel resorcyclide as anticancer agent based on Hsp90 inhibition
- Inhibition of heat shock protein 90 (Hsp90) as a therapeutic strategy for the treatment of myeloma and other cancers
- UBR1 promotes protein kinase quality control and sensitizes cells to Hsp90 inhibition
- S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities
- Blocking NF-κB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death
- Hsp90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas
- Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest
- Hsp90 inhibition and the expression of phenotypic variability in the rainforest species Drosophila birchii
- Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells
- Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines
- Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone
- Intrinsic inhibition of the Hsp90 ATPase activity
- Resistance to Hsp90 inhibition involving loss of MCL1 addiction
- Hsp90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia
- PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
- Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition
- Molecular mechanism of inhibition of the human protein complex Hsp90–Cdc37, a kinome chaperone–cochaperone, by triterpene celastrol
- Inhibition of Hsp90 function delays and impairs recovery from heat shock
- Hsp90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
- Inhibition of Hsp90 as a special way to inhibit protein kinases
- Disruption of zebrafish somite development by pharmacologic inhibition of Hsp90
- Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex
- 18β-Glycyrrhetinic acid potentiates Hsp90 inhibition-induced apoptosis in human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial
- Effect of heat-shock protein-90 (Hsp90) inhibition on human hepatocytes and on liver regeneration in experimental models
- Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by Hsp90 inhibition
- Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines
- Inhibition of Hsp90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer
- 5-Episinuleptolide acetate, a norcembranoidal diterpene from the formosan soft coral Sinularia sp., induces leukemia cell apoptosis through Hsp90 inhibition
- Heat shock protein 90 (Hsp90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of …
- Influence of Hsp90 and HDAC inhibition and tubulin acetylation on perinuclear protein aggregation in human retinal pigment epithelial cells
- 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation
- Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol
- Destabilization of PDK1 by Hsp90 inactivation suppresses hepatitis C virus replication through inhibition of PRK2-mediated viral RNA polymerase phosphorylation
- Pharmacologic and genetic inhibition of Hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor …
- Inhibition of Hsp90 with Pochoximes: SAR and Structure‐Based Insights
- Hsp90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo
- Inhibition of GR‐mediated transcription by p23 requires interaction with Hsp90
- Inhibition of heat shock protein 90 (Hsp90) in proliferating endothelial cells uncouples endothelial nitric oxide synthase activity
- Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to Hsp90 inhibition
- Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells
- Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition
- Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G2/M arrest in glioblastoma cell lines
- The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition
- Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90
- Inhibition of Hsp90 by AUY922 preferentially kills mutant KRAS colon cancer cells by activating Bim through ER stress
- Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma
- Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
- Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of Hsp90 inhibition in an in vivo squamous cell carcinoma model
- Blocking the survival of the nastiest by Hsp90 inhibition
- Dynamic cycling with Hsp90 stabilizes neuronal nitric oxide synthase through calmodulin-dependent inhibition of ubiquitination
- Hsp90 inhibition induces both protein-specific and global changes in the ubiquitinome
- Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma
- Oxidative inhibition of Hsp90 disrupts the super‐chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo
- Induction of heat shock protein HSPA6 (HSP70B′) upon Hsp90 inhibition in cancer cell lines
- Blocking the heat shock response and depleting HSF-1 levels through heat shock protein 90 (Hsp90) inhibition: a significant advance on current Hsp90 …
- Hsp90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo
- Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
- Inhibition of Hsp90 could be possible mechanism for anti-cancer property of amniotic membrane
- Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90
- Calpain genetic disruption and Hsp90 inhibition combine to attenuate mammary tumorigenesis
- Hsp90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer
- Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma
- Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma
- Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA …
- Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration
- The interplay between inhibition of JAK2 and HSP90
- Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol
- Inhibition of cell death by a novel 16.2 kD heat shock protein predominantly via Hsp90 mediated lipid rafts stabilization and Akt activation pathway
- Hsp90 binds directly to fibronectin (FN) and inhibition reduces the extracellular fibronectin matrix in breast cancer cells
- Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
- Hsp90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents
- Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells
- Synthesis of flavokawain analogues and their anti-neoplastic effects on drug-resistant cancer cells through Hsp90 inhibition
- Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature
- Inhibition of Hsp90 with resorcylic acid macrolactones: synthesis and binding studies
- Combined BRAF and Hsp90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma
- Down-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells
- Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities
- Inhibition of HSP90‐dependent telomerase activity in amyloid β‐induced apoptosis of cerebral endothelial cells
- Hsp90 inhibition in HER2-positive breast cancer cells
- Synthesis of butein analogues and their anti-proliferative activity against gefitinib-resistant non-small cell lung cancer (NSCLC) through Hsp90 inhibition
- Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70
- Inhibition of heat shock protein 70 and 90 (Hsp70 and Hsp90) in target spesific cancer treatment
- Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy
- Combined inhibition of extracellular signal-regulated kinases and Hsp90 sensitizes human colon carcinoma cells to ionizing radiation
- Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR
- Identification of mixed lineage leukemia 1 (MLL1) protein as a coactivator of heat shock factor 1 (HSF1) protein in response to heat shock protein 90 (Hsp90) inhibition
- Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma
- Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
- Hsp90 inhibition suppresses NF-κB transcriptional activation via Sirt-2 in human lung microvascular endothelial cells
- Concomitant inhibition of HSP90, its mitochondrial localized homologue TRAP1 and HSP27 by green tea in pancreatic cancer HPAF‐II cells
- Prospective identification of resistance mechanisms to Hsp90 inhibition in KRAS mutant cancer cells
- Hsp90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal …
- Co-inhibition of HSP70/Hsp90 synergistically sensitizes nasopharyngeal carcinoma cells to thermotherapy
- EGFR Exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas
- Boosting the effects of hyperthermia-based anticancer treatments by Hsp90 inhibition
- Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma
- Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition
- AIDing cancer treatment: reducing AID activity via Hsp90 inhibition
- Pharmacological inhibition of Hsp90 and ras activity as a new strategy in the treatment of HNSCC
- Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses
- Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
- Pharmacological inhibition of Hsp90 activity negatively modulates myogenic differentiation and cell survival in C2C12 cells
- Hsp90 inhibition results in glucocorticoid receptor degradation in association with increased sensitivity to paclitaxel in triple-negative breast cancer
- … β peptide-induced inhibition of endothelial nitric oxide production involves oxidative stress-mediated constitutive eNOS/Hsp90 interaction and disruption of …
- Hsp90 inhibition renders iNOS aggregation and the clearance of iNOS aggregates by proteasomes requires SPSB2
- Hsp90 inhibition without heat shock response
- Hsp90-mediated inhibition of FKBP38 regulates apoptosis in neuroblastoma cells
- Reactive oxygen species-dependent Hsp90 protein cleavage participates in arsenical As+ 3-and MMA+ 3-induced apoptosis through inhibition of telomerase activity …
- Sulphoxythiocarbamates modify cysteine residues in Hsp90 causing degradation of client proteins and inhibition of cancer cell proliferation
- Inhibition of Hsp90 attenuates porcine reproductive and respiratory syndrome virus production in vitro
- Magnetic nanoparticle-mediated hyperthermia therapy induces tumour growth inhibition by apoptosis and Hsp90/AKT modulation
- Changes in heat-shock protein synthesis and thermotolerance of Arabodopsis thaliana seedlings resulting from Hsp90 inhibition by geldanamycin
- Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib …
- Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma
- Inhibition of Plasmodium falciparum Hsp90 Contributes to the Antimalarial Activities of Aminoalcohol-carbazoles
- Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion
- Hsp90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome
- Strong antitumor synergy between DNA crosslinking and Hsp90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells
- Inhibition and flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced …
- Inhibition of Hsp90 attenuates pro-inflammatory cytokines and prevents LPS induced liver injury
- Little effect of Hsp90 inhibition on the quantitative wing traits variation in Drosophila melanogaster
- Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a Hsp90-dependent manner
- Tomato plant cell death induced by inhibition of Hsp90 is alleviated by Tomato yellow leaf curl virus infection
- Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy
- Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro
- Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer
- Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG
- Efficacy of Hsp90 inhibition for the induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo
- In silico investigations on Hsp90 and its inhibition for the therapeutic prevention of breast cancer
- … not HSP90, confers neuroprotection against fatal endotoxemia via augmentation of nitric-oxide synthase I (NOS I)/protein kinase G signaling pathway and inhibition of …
- Hsp90 inhibition suppresses PGE2 production via modulating COX-2 and 15-PGDH expression in HT-29 colorectal cancer cells
- Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells
- Targeting the MYC oncogene in Burkitt lymphoma through Hsp90 inhibition
- Hsp90 inhibition induces destabilization of actin cytoskeleton in tumor cells: functional significance of Hsp90 interaction with F–actin
- Ascorbic acid inhibition of Candida albicans Hsp90-mediated morphogenesis occurs via the transcriptional regulator Upc2
- The targeted inhibition of mitochondrial Hsp90 overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis
- Bioactive metabolites from Chaetomium aureum: Structure elucidation and inhibition of the Hsp90 machine chaperoning activity
- Heat shock protein 90 (Hsp90) inhibition in acute myeloid leukemia—Targeting of disease heterogeneity through direct and indirect antileukemic effects
- HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging
- Selective Inhibition of HDAC6 regulates preferential cytotoxicity in cancer cells by modulating p53 and Hsp90 stability
- 2-Aroylquinoline-5, 8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (Hsp90) inhibition
- Epigenetic effects of inhibition of heat shock protein 90 (Hsp90) in human pancreatic and colon cancer
- Quantitative proteomics reveals molecular mechanism of gamabufotalin and its potential inhibition on Hsp90 in lung cancer
- Hsp90 inhibition affects cell metabolism by disrupting mitochondrial protein insertion
- Drug-induced Hsp90 inhibition alleviates pain in monoarthritic rats and alters the expression of new putative pain players at the DRG
- Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane
- Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines.
- Hyponatremia and V2 vasopressin receptor upregulation: a result of Hsp90 inhibition
- Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90
- … inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 …
- Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome
- Hsp90 inhibition drives degradation of FGFR2 fusion proteins: Implications for treatment of cholangiocarcinoma
- Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation
- Inhibition of Heat Shock proteins Hsp90 and HSP70 induce oxidative stress, suppressing cotton fiber development
- Hsp90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC
- MicroPET/CT imaging of AXL downregulation by Hsp90 inhibition in triple-negative breast cancer
- Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
- Radicicol binding to Swo1/Hsp90 and inhibition of growth of specific temperature-sensitive cell cycle mutants of fission yeast
- Hsp90 inhibition results in a significant delay in tumor progression in a model of emerging EGFR TKI resistance in non-small cell lung cancer
- Inhibition of Hsp90 promotes neural stem cell survival from oxidative stress through attenuating NF-κB/p65 activation
- … docking analysis of the molecular chaperone-kinase interactions: Towards allosteric inhibition of protein kinases by targeting the Hsp90-Cdc37 chaperone machinery
- Phenotypic variability of Arabidopsis thaliana seedlings as a result of inhibition of Hsp90 chaperones
- Antiangiogenic effects associated with the inhibition of Hsp90 in colorectal cancer
- Hsp90 inhibition is a potential therapeutic strategy in treatment of adenocarcinoma of the esophagus
- Hsp90 inhibition as an anticancer strategy: Novel approaches and future directions
- 17-DMAG-loaded nanofibrous scaffold for effective growth inhibition of lung cancer cells through targeting Hsp90 gene expression
- Geldanamycin derivatives as promising anticancer drugs: therapy via Hsp90 inhibition
- Effect of Hsp90 inhibition on Rac activation, cell migration, tumor growth and liver metastasis of human pancreatic carcinoma
- Targeted inhibition of mitochondrial Hsp90 induces mitochondrial elongation in Hep3B hepatocellular carcinoma cells undergoing apoptosis by increasing …
- Traditional and novel mechanisms of heat shock protein 90 (Hsp90) inhibition in cancer chemotherapy including Hsp90 cleavage
- Simultaneous inhibition of Hsp90 and mTOR synergistically reduces tumor growth and angiogenesis of hepatocellular cancer in an experimental model
- … sesterterpenoid-type metabolite, induces apoptosis in prostate LNcap cells via oxidative and ER stress combined with the inhibition of topoisomerase II and Hsp90
- AMH and AMHR2 regulate survival signaling, epithelial-mesenchymal transition (EMT) and resistance to Hsp90 inhibition in non-small cell lung cancer (NSCLC)
- Hsp90 Inhibition Reduces TLR5 Surface Expression and NF-κB Activation in Human Myeloid Leukemia THP-1 Cells
- Overcoming acquired resistance to Hsp90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
- Evaluating dual Hsp90 and Hsp70 inhibition as a cancer therapy
- Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition
- Correction: Strong antitumor synergy between DNA crosslinking and Hsp90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells
- Changes in heat shock protein synthesis and thermotolerance of Arabidopsis thaliana seedlings as a result of inhibition of Hsp90 by geldanamycin
- Novel and less explored chemotypes of natural origin for the inhibition of Hsp90
- Hsp90 inhibition attenuates LPS-mediated NF-κB-dependent gene activation by preventing the de-acetylation and maintaining the DNA binding of acetyl-histone H3 …
- Hsp90-mediated inactivation of NF {kappa} B switches autophagy to apoptosis through becn1 transcriptional inhibition in selenite-induced NB4 cells
- … yeast into whether the rapamycin inhibition of heat shock transcription factor (Hsf1) can prevent the Hsf1 activation that results from treatment with an Hsp90 …
- Celastrol Mediated Hsp90 Protein Inhibition in Cancer
- Downregulation of androgen receptors by NaAsO2 via inhibition of AKT‐NF‐κB and Hsp90 in castration resistant prostate cancer
- Transcriptomics-based screening identifies pharmacological inhibition of Hsp90 as a means to defer aging
- Enhanced HIF1α inhibition through dual inhibition of CDK and HSP90
- Hsp90 N-and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells
- Inhibition of Hsp90 by triptolide (TPL) augments Bortezomib-induced U266 cells apoptosis
- Hsp90 inhibition promotes proteasome function in vascular endothelial cells
- Inhibition of elemene on Hsp90/Raf-1 molecular complex in C6 glioblastoma cells [J]
- Targeted Inhibition Of Mitochondrial Hsp90 Improves Pulmonary Arterial Hypertension
- The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs
- Epilepsy: Hsp90 inhibition suppresses seizures
- A scaffold merging approach to Hsp90 C-terminal inhibition: synthesis and evaluation of a chimeric library
- Hsp90 Inhibition Reverts IL13-and IL17-Induced Goblet Cell Metaplasia in Human Airway Epithelia
- INVESTIGATION OF THE CELLULAR EFFECTS OF Hsp90 INHIBITION ON HEPATOCELLULAR CARCINOMA CELLS
- RNAi knockdown or chemical inhibition of anaphase-promoting complex components is synthetic lethal with Hsp90 inhibition
- Inhibition Of Hsp90 Repairs The LPS-Induced Ali In Mice
- A comprehensive study to analyze tumor sensitivity to Hsp90 inhibition therapy.
- Trypanosoma cruzi Inhibition of Hsp90 in
- Acquired resistance to Hsp90 inhibition in triple-negative breast cancer
- Inhibition of Hsp90 in Streptomyces coelicolor
- Hsp90 inhibition affects MHC class II presentation of glutamic acid decarboxylase
- Role of PRKD2 in Hsp90 inhibition-mediated suppression of cancer growth
- MRS detection of altered choline metabolism following Hsp90 inhibition
- Hsp90 inhibition radiosensitize head and neck carcinoma via EGFR degradation
- Impact of Hsp90 Inhibition on Viability and Cell Cycle in Relation to p53 Status
- Preclinical efficacy of Hsp90 inhibition by using PF-04942847 in osteosarcoma
- CLU inhibition using OGX-011 is a new adjuvant therapeutic strategy for Hsp90 inhibition in prostate cancer
- Dual inhibition of CDK1 and Hsp90 destabilizes HIF1α and synergistically induces cancer cell death
- Functional inhibition of Hsp90 potentiates the effects of ionizing radiation in colorectal cancer
- Combining Hsp90 Inhibition with Standard Therapies for HER2 Positive Breast Cancer.
- The new molecular target therapy of Hsp90 inhibition in esophageal squamous cell carcinoma
- Hsp90 inhibition decreases ovarian cancer cell proliferation and potentiates platinum sensitivity
- Hsp90 inhibition down regulates EGFR and its effector signaling proteins in pancreatic cancer cell lines
- Synthetic lethal screen identifies candidates that modulate cancer cell sensitivity in response to Hsp90 inhibition.
- CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for Hsp90 inhibition in prostate cancer.
- Inhibition of Hsp90 suppresses BmNPV replication in Bombyx mori
- … : Modulation of the Hsp90 cochaperone carboxy‐terminus HSC70‐interacting protein (CHIP) increases cellular sensitivity to heat shock protein 90 (Hsp90) inhibition
- Heat shock protein 90 (Hsp90) inhibition reduces glomerular filtration rate (GFR) and sodium excretion.
- Changes in choline metabolism as potential biomarkers of Hsp90 inhibition in NEU/HER2-driven mammary carcinoma Oncomouse® cells
- Hsp90 acetylation following histone deacetylase inhibition: A role for the histone acetyltransferases p300 and PCAF
- A67 BREAKDOWN: THE CELLULAR CONTRIBUTION TO PULMONARY HYPERTENSION: Targeted Inhibition Of Mitochondrial Hsp90 Improves Pulmonary Arterial …
- HDAC and Hsp90 inhibition as therapeutic strategy for translocation renal cell carcinoma
- Hsp90 inhibition leads to a differential proteomics profile in non small cell lung cancer cell lines
- THU0057 Inhibition of Heat Shock Protein 90 (Hsp90) Prevents Fibrosis by Targeting Canonical TGF-B Signaling
- Immunostimulatory effects of Hsp90 inhibition: Insights from combinational immunotherapies targeting EphA2
- Proteomic analysis of ubiquitination identifies the interplay between Hsp90 inhibition and CUL5 in the control of autophagy
- TREATMENT OF AVIAN TIBIAL DYSCHONDROPLASIA USING TRADITIONAL CHINESE MEDICINES BY Hsp90 INHIBITION
- Supplementary Materials: Targeting the MYC Oncogene in Burkitt Lymphoma through Hsp90 Inhibition
- Abstract B16: Phenotypic plasticity in the EML cell culture system as a result of Hsp90 inhibition
- Visualizing dual downregulation of IGF-1R and VEGF by Hsp90 inhibition effect in triple negative breast cancer
- Hsp90 Inhibition Leads to the Degradation of O-Linked N-Acetylglucosamine Transferase and to the Reduction of O-GlcNAcylation
- Effect of Hsp90 inhibition in tumor cells Apoptosis and cell migration
- HER2-overexpressing lines are sensitive to Hsp90 inhibition irrespective of p53 status
- Analysis of cell cycle-related gene expressions in MDM2-transfected LNCaP-MST cells after inhibition of HSP90
- Inhibition of Hsp90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer
- Cellular and molecular effects of Hsp90 inhibition by 17-AAG in sporadic and hereditary breast cancer
- Hsp90 Inhibition and Cellular Stress Elicits Phenotypic Plasticity in Hematopoietic Differentiation
- Therapeutic inhibition of Hsp90 in a mouse model of diabetic atherosclerosis and nephropathy
- Slow, tight binding inhibition of Hsp90 isoforms correlates with potent anti-proliferative activity in cancer cell lines
- Empirical Modeling the Effect of Hsp90 Inhibition on Cytokines Associated With Impaired Biotransport of Apoptotic Debris
- Effect of Hsp90 inhibition on the gene expression profile of MDM2 transfected LNCaP-MST prostate cancer cells
- Evaluation of biomarkers for imaging and radio-immunotherapy in combination with Hsp90 inhibition in squamous cell carcinomas
- 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
- Novobiocin–ferrocene conjugates possessing anticancer and antiplasmodial activity independent of Hsp90 inhibition
- A62 LUNG FIBROSIS: FIBROBLAST BIOLOGY: Hsp90 Inhibition Prevents Lung Fibroblast Activation And Epithelial-Mesenchymal Transition
- Abstract P4-16-05: Hsp90 inhibition potentiates chemotherapy effectiveness in triple negative breast cancer: Role of glucocorticoid receptor signaling
- Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activities
- Hsp90 inhibition rescues behavioral deficits and reduces tau phosphorylation in ps19 mice model for Alzheimer’s disease (AD)
- Inhibition of heat shock protein 90 (Hsp90) and degradation of client proteins associated with oncogenesis using analogs of Novobiocin
- Hsp90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase
- Hsp90 inhibition ameliorates CD4+ T cell‐mediated acute Graft versus Host disease in mice
- Hsp90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics
- Computational modeling of Hsp90 inhibition illustrates a potential therapy to inhibit immune-mediated inflammation in systemic lupus erythematosus.(87.8)
- Hsp90 inhibition suppresses LPS-mediated NFkB target gene expression without affecting NFkB nuclear translocation in human lung microvascular endothelial cells
- Hsp90 inhibition induced cytotoxicity via downregulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells
- Hsp90 inhibition abolishes LPS-mediated NF-κB transcriptional activation independent of IKKβ in human lung microvascular endothelial cells (HLMVEC)(847.7)
- Hsp90 inhibition prevents bacterial lipopolysaccharide-induced and RhoA-mediated signaling leading to paracellular hyper-permeability in human lung microvascular …
- USP22-dependent HSP90AB1 expression promotes resistance to Hsp90 inhibition in mammary and colorectal cancer
- Role for NQO1 and MnSOD in 17AAG-Induced Hsp90 inhibition in Pancreatic Cancer Cells
- Hsp90 inhibition results in GR, AR and JAK protein degradation, decreased triple-negative breast cancer proliferation and increased paclitaxel sensitivity
- Hsp90 inhibition prevents monocrotaline-induced pulmonary hypertension in rats, as revealed by high resolution echocardiography
- Correction: 2-Aroylquinoline-5, 8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (Hsp90) inhibition
- Compromising the constitutive p16INK4a expression sensitizes human neuroblastoma cells to Hsp90 inhibition and promotes premature senescence
- Hsp90 Inhibition Enhances the Anti-Tumor Efficacy of Combination Chemo Immunotherapy Targeting DNA Repair Proteins
- Casting a wide net: Hsp90 inhibition to circumvent resistance to TKIs in EGFR-mutated and ALK-rearranged NSCLC
- Hsp90 inhibition attenuates the LPS-mediated phosphorylation of CREB and STAT3 in human lung microvascular endothelial cells
- Ligand-independent activation of the P2X7 receptor by Hsp90 inhibition stimulates motor neuron apoptosis
- Abstract# 2835: Inhibition of heat shock protein 90 (Hsp90) modulates macrophage stimulating-1 receptor (MSR1) expression and signaling, and reduces pancreatic …
- Pharmacological Inhibition of Hsp90 as a Novel Antitumor Strategy to Target Cytoarchitecture Through Extracellular Matrix Signaling
- Metabolic profiling of drug response in prostate cancer cells following PI3K, MAPK and Hsp90 inhibition using magnetic resonance spectroscopy
- 17-AAG Hsp90 Inhibition as an Effective Therapy for Lymphoma Stem Cells.
- Chemical inhibition of Hsp90 inhibits TNF‐α mediated proliferation and induces apoptosis in human rheumatoid arthritis fibroblast‐like synoviocytes
- Integration of Hsp90 inhibition in combinational immunotherapies targeting receptor tyrosine kinase EphA2
- 17-AAG Mediated Hsp90 Inhibition as an Effective Therapy for Lymphoma Stem Cells
- A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to Hsp90 Inhibition
- Visualizing dual downregulation of IGF-1 R and VEGF-A by Hsp90 inhibition effect in triple negative breast cancer
- Abstract A226: ImmunoPET with 89Zr‐DFO‐trastuzumab: Monitoring the pharmacodynamic effects on HER2/neu expression by Hsp90 inhibition in vivo
- Effects of Hsp90 inhibition and/or PKC activation on ErbB2 in MDA-MB-453 cells
- Abstract B103: Hsp90 inhibition targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell carcinoma …
- Abstract P1-03-07: Differential Effect of Specific p53 Mutations on Breast Cancer Growth and Response to Hsp90 Inhibition In Vivo
- … # 4975: Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat shock protein 90 (Hsp90) inhibition
- Effect of heat stress and Hsp90 inhibition on T-type calcium currents and voltage-dependent potassium currents in leydig cells
- This is a repository copy of FGFR3 translocations in bladder cancer: differential sensitivity to Hsp90 inhibition based on drug metabolism..
- B28 BARRIER DYNAMICS IN THE PULMONARY CIRCULATION: Hsp90 Inhibition Suppresses Bacterial Endotoxin-Mediated Nf-[kappa] b Transcriptional Activation …
- Abstract B140: Positron emission tomography imaging of HER2 expression and pharmacodynamic response to Hsp90 inhibition with the next-generation ZHER2 …
- Inhibition of heat-shock protein 90 (Hsp90) disrupts mutliple pro-angiogenic signaling pathways in gastric cancers cells in vitro and reduces tumor growth and …
- Hsp90 Inhibition Abrogates the Topoisomerase I Poison-induced G2/M Checkpoint in p53-null Tumor cells by Depleting Chk1 and Wee1
- Heat Shock Protein 90 (Hsp90) Inhibition as a Potential Novel Approach to the Treatment of Patients with ALK Mutated Non-small Cell Lung Cancer (NSCLC)
- MP64-14 TARGETING HEAT SHOCK FACTOR 1 SENSITIZES CASTRATION-RESISTANT PROSTATE CANCER CELLS TO Hsp90 INHIBITION IN PART BY …
- … mutation of PI3K p110alpha subunit in HER2-overexpressing mammary epithelial cells confers a”” stem-like”” phenotype and acute sensitivity to Hsp90 inhibition
- Heat shock protein 90 (Hsp90) inhibition in squamous cell carcinoma of the head and neck (SCCHN): An in vitro analysis with a focus on p16 status.
- Inhibition of Hsp90 by AT13387 Delays the Emergence of
- Acetylation of Hsp90 reverses dexamethasone-mediated inhibition of insulin secretion
- Local Inhibition of Hsp90 to Prevent Intimal Hyperplasia after Balloon Injury
- Combination of Hsp90 and mTOR inhibition promotes pancreatic cancer growth inhibition
- Hsp90 characterization and inhibition: a multi-methodological study
- Immune Expression and Inhibition of Hsp90 in Retinoblastoma
- Immune Expression and Inhibition of Hsp90 in Metastatic Uveal Melanoma
- Therapeutic advantages of inhibition of Hsp90 and proteasomal inhibition in prostate cancer cells
- Immune expression and inhibition of Hsp90 in uveal melanoma
- Synthesis of Novel Hsp90 Inhibotor and Its Inhibition
- Immune Expression and Inhibition of Hsp90 in Human Uveal Melanoma
- Reduction of cardiac TGFβ-mediated profibrotic events by inhibition of Hsp90 with engineered protein
- Inhibition of Hsp90 induces BRCA1 degradation and hypersensitivity to ionizing radiation
- Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of Hsp90 family proteins
- Therapeutic Inhibition Of Hsp90 Attenuates Fibroblast Activation Involved In Severe Fibrotic Lung Disease
- Inhibition of curcumin derivative C1209 on proliferation of CML cells by disrupting Hsp90 chaperon function
- Low-level inhibition of Hsp90 forces cells to tip their (antigenic) hand
- Induction of enhanced tumor-specific immunity by Hsp90 targeted photodynamic therapy (Hsp90-PDT) combined with immune checkpoint inhibition
- Inhibition of Hsp90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells
- Combinatorial inhibition of mTORC2 and Hsp90 leads to a distinctly effective therapeutic strategy in malignant pheochromocytom.
- Abstract B99: Targeting TPR cochaperones of the Hsp90 molecular chaperone complex for specific inhibition.
- The stress protein response transiently inhibits STAT1 signaling via inhibition of Hsp90 binding
- Inhibition of Hsp90 sensitizes pancreatic cancer in vitro and in vivo to chemo-radiotherapy
- Targeted blockade of Hsp90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition
- HSP70/Hsp90 Expression in CA9-22 after thermotherapy and the effect of inhibition of HSP70/Hsp90 expression on the efficacy of thermotherapy
- INHIBITION OF Hsp90 IN TRYPANOSOMA BRUCEI AND PHARMACOKINETIC-
PHARMACODYNAMIC RELATIONSHIPS OF ANTITRYPANOSOMALS - Inhibition of Hsp90 chaperone and 26S proteasomal activities by efrapeptins in breast cancer cells
- Functional inhibition of Hsp90 induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer
- Inhibition of heat shock protein 90 (Hsp90) by diterpenoids from roots of Zhumeria majdae
- C76 HEAT SHOCK PROTEIN: Therapeutic Inhibition Of Hsp90 Attenuates Fibroblast Activation Involved In Severe Fibrotic Lung Disease
- Inhibition of novobiocin on proliferation of HL-60/Bcr-Abl cells involves disruption of Hsp90 chaperon function
- 292 INHIBITION OF Hsp90 AGGRAVATES THE EFFECTS OF HEAT SHOCK ON DEVELOPMENTAL COMPETENCE OF BOVINE OOCYTES
- V599E B-Raf as the next Hsp90 client protein: A novel strategy for selective inhibition of mutated B-Raf
- Inhibition of Hsp90 enhances T cell-mediated antitumor immune responses through expression of interferon-alpha response Genes
- Hsp90 protects LPS induced pancreatic inflammation of AR42J cells by inhibition of p38MAPK/NF-κB pathways
- Inhibition of Hsp90 with NVP-AUY922 induces a synergistic effect in HER2-amplified, trastuzumab-resistant breast and gastric cancer
- Inhibition of histone deacetylases 1 and 2 increases p21CIP1/WAF1 expression independent of p53 and Hsp90 in colon cancer cells
- Inhibition of Hsp90 and its Client Kinase FAK has Therapeutic Potential in Squamous Cell Carcinomas of the Uterine Cervix and Oral Cavity
- In vitro and in vivo inhibition of the Hsp90 molecular chaperone by novel, synthetic, potent pyrazole/isoxazole resorcinol 5-amide analogs
- Combined Pharmacological Inhibition of Cyclophilins, FK506-Binding Proteins, Hsp90, and Hsp70 Protects Cells From Clostridium botulinum C2 Toxin
- Inhibition of Hepatitis C Replication by Targeting the Molecular Chaperone Hsp90: Synthesis and Biological Evaluation of 4,5,6,7‐Tetrahydrobenzo[1,2‐d]
thiazole … - Benzo [a] pyrene Inhibition of Follicular Development and Survival Is Associated with Dysregulation of Hsp90, Bax, CYP1A1, and CYP1B1 Expression.
- Inhibition of heat stress-related apoptosis of chicken myocardial cells through inducing Hsp90 expression by aspirin administration in vivo
- Abstract NT-094: TARGETED INHIBITION OF Hsp90 IMPAIRS DNA-DAMAGE RESPONSE PROTEINS AND INCREASES THE SENSITIVITY OF OVARIAN …
- Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/Hsp90 signaling axis
- Inhibition of heat shock protein 90 (Hsp90) sensitizes HER2-negative breast cancer derived MDA-MD-231 cell line to the cytotoxic effect of troglitazone (TRO)
- Effects of Hsp90 inhibition on galectin3 expression in human monocytic cell line THP1
- Radiosensitization of human tumor cells by Hsp90 inhibition
- Hsp90 inhibition as a way to treat cancer
- Hsp90 inhibition causes heterochronies in the skull ossification sequences of Pleurodeles waltl (Urodela). Evolutionary implications.
- Hsp90 Inhibition verbessert die antitumor Effektivität von Rapamycin durch Blockade von Akt und NF-κB
- Inhibition von Hsp90 in Gemcitabine-und 5-Fluorouracil-resistenten Pankreaskarzinomen
- Inhibition of Hsp90 with pochoximes: structure-activity relationship and structure-based insights
- Inhibition von Heat-shock Protein 90 ( Hsp90 ) mittels EC154, einem neuen synthetischen Hsp90 Antagonist, reduziert das Wachstum von humanen Magen-und…
- VII. Molekulare Onkologie: Therapie Inhibition von Heat-shock Protein 90 ( Hsp90 ) mittels EC154, einem neuen synthetischen Hsp90 Antagonist, reduziert das…
- Design and synthesis of a library of cyclopeptides and Shepherdine analogues for the inhibition of the Hsp90 -Survivine interaction
- A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitorshttps://www.nature.
com/articles/nature01913 - Hsp90 inhibitors as novel cancer chemotherapeutic agents
- Hsp90 molecular chaperone inhibitors: are we there yet?
- Development and application of Hsp90 inhibitors
- Targeting Hsp90: small-molecule inhibitors and their clinical development
- Inhibitors of the Hsp90 molecular chaperone: current status
- Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function
- Update on Hsp90 inhibitors in clinical trial
- Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
- Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket
- V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
- Hsp90 inhibitors in the clinic
- Discovery and development of pyrazole-scaffold Hsp90 inhibitors
- Hsp90 inhibitors identified from a library of novobiocin analogues
- Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
- The stress response: implications for the clinical development of Hsp90 inhibitors
- Natural product origins of Hsp90 inhibitors
- Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive
- Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy
- Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation
- Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design
- Development of purine-scaffold small molecule inhibitors of Hsp90
- Hsp90 inhibitors reduce influenza virus replication in cell culture
- Hsp90 inhibitors: current development and potential in cancer therapy
- The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3, 4-diarylpyrazole class of Hsp90 inhibitors
- Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors
- Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice
- Genetic resistance to JAK2 enzymatic inhibitors is overcome by Hsp90 inhibition
- Recent advances in Hsp90 inhibitors as antitumor agents
- New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential
- Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors
- Structure-based discovery of a new class of Hsp90 inhibitors
- Effectiveness of Hsp90 inhibitors as anti-cancer drugs
- Maximizing the therapeutic potential of Hsp90 inhibitors
- Purine-scaffold Hsp90 inhibitors
- Hsp90 inhibition accelerates cell lysis anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide-and Hsp90-dependent …
- Emerging Hsp90 inhibitors: from discovery to clinic.
- Discovery and design of novel Hsp90 inhibitors using multiple fragment‐based design strategies
- A fluorescence polarization assay for inhibitors of Hsp90
- Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2
- Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification
- Auditing the Pharmacological Accounts for Hsp90 Molecular Chaperone Inhibitors: Unfolding the Relationship between Pharmacokinetics and Pharmacodynamics1
- Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs
- Discovery and development of purine-scaffold Hsp90 inhibitors
- Brain-permeable small-molecule inhibitors of Hsp90 prevent α-synuclein oligomer formation and rescue α-synuclein-induced toxicity
- Design, synthesis, and biological evaluation of Hsp90 inhibitors based on conformational analysis of radicicol and its analogues
- Identification of Hsp90 inhibitors as a novel class of senolytics
- Inhibitors of Hsp90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
- Using natural product inhibitors to validate Hsp90 as a molecular target in cancer
- Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors
- Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to Hsp90 inhibitors
- Fragment‐based identification of Hsp90 inhibitors
- 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential Hsp90 inhibitors
- Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors
- 3-(5-Chloro-2, 4-dihydroxyphenyl)-pyrazole-4-
carboxamides as inhibitors of the Hsp90 molecular chaperone - Inhibitors of Hsp90 and other chaperones for the treatment of cancer
- Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 Nterminal ATP binding site
- High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase
- Insights into designing the dual-targeted HER2/Hsp90 inhibitors
- Hsp90 inhibitors as promising agents for radiotherapy
- p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity
- A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues
- Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors
- Inhibitors of the Hsp90 molecular chaperone: attacking the master regulator in cancer
- Adenine derived inhibitors of the molecular chaperone HSP90—SAR explained through multiple X-ray structures
- Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors
- Identification of new biomarkers for clinical trials of Hsp90 inhibitors
- Hsp90 inhibitors for cancer therapy and overcoming drug resistance
- BRAF and NRAS mutations in melanoma: potential relationships to clinical response to Hsp90 inhibitors
- Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells
- Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development
- Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors
- Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line
- A novel class of Hsp90 inhibitors isolated by structure-based virtual screening
- Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90
- Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors: Miniperspective
- Hsp90 inhibitors in breast cancer: a systematic review
- Hsp90 inhibitors deplete key anti‐apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin
- Natural product inhibitors of Hsp90: potential leads for drug discovery
- Purine-scaffold Hsp90 inhibitors.
- Medicinal chemistry of Hsp90 inhibitors
- Hsp90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy
- Synthesis and evaluation of Hsp90 inhibitors that contain the 1, 4-naphthoquinone scaffold
- Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran …
- Geldanamycin and its derivatives as Hsp90 inhibitors
- High-throughput screening for Hsp90 ATPase inhibitors
- Preclinical characterization of mitochondria-targeted small molecule Hsp90 inhibitors, gamitrinibs, in advanced prostate cancer
- Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma
- Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone
- Development of a high throughput drug screening assay for the detection of changes in tau levels-proof of concept with Hsp90 inhibitors
- Targeting the Hsp90 chaperone: synthesis of novel resorcylic acid macrolactone inhibitors of Hsp90
- Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (Hsp90) molecular chaperone
- Structure‐based and in silico design of Hsp90 inhibitors
- Hsp90 and its inhibitors
- Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors
- Novel Hsp90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair …
- Natural Product Inspired N‐Terminal Hsp90 Inhibitors: From Bench to Bedside?
- Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines
- Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer‐initiating cells
- Genes and proteins governing the cellular sensitivity to Hsp90 inhibitors: a mechanistic perspective
- Hsp90 inhibitors: clinical development and future opportunities in oncology therapy.
- Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives
- Targeting of KRAS mutant tumors by Hsp90 inhibitors involves degradation of STK33
- An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors
- Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism
- Constitutively-active androgen receptor variants function independently of the Hsp90 chaperone but do not confer resistance to Hsp90 inhibitors
- An AlphaScreenTM-Based High-Throughput Screen to Identify Inhibitors of Hsp90-Cochaperone Interaction
- Assays for Hsp90 and inhibitors
- N-Aryl-benzimidazolones as novel small molecule Hsp90 inhibitors
- Molecular basis for the actions of Hsp90 inhibitors and cancer therapy
- Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus
- Synthesis of pochoxime prodrugs as potent Hsp90 inhibitors
- Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells
- Inside the Hsp90 inhibitors binding mode through induced fit docking
- … 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90β, a property that can be exploited in screens for new Hsp90 chaperone inhibitors
- Learning from nature: advances in geldanamycin-and radicicol-based inhibitors of Hsp90
- Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (Hsp90) inhibitors targeting proliferation and angiogenesis
- Hsp90 inhibitors and drugs from fragment and virtual screening
- Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression
- Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax
- … of Hsp90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
- Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway
- Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series
- A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors
- Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors
- Anticancer inhibitors of Hsp90 function: beyond the usual suspects
- Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors
- Hsp90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors
- Inhibition of Hsp90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma …
- Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 …
- Tricyclic Series of Heat Shock Protein 90 (Hsp90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-c]pyridines as Potent Inhibitors of the Hsp90 Molecular …
- Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors
- A Chemical–Biological Study Reveals C9-type Iridoids as Novel Heat Shock Protein 90 (Hsp90) Inhibitors
- Exploring the binding site of C-terminal Hsp90 inhibitors
- 5-Aryl-4-(5-substituted-2, 4-dihydroxyphenyl)-1, 2, 3-thiadiazoles as inhibitors of Hsp90 chaperone
- Organelle-specific Hsp90 inhibitors
- Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells
- Hsp90 inhibitors as therapy for multiple myeloma
- Isoxazolo (aza) naphthoquinones: A new class of cytotoxic Hsp90 inhibitors
- Combining trail with PI3 kinase or Hsp90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling
- Hsp90 inhibitors as new leads to target parasitic diarrheal diseases
- Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone
- Impact of posttranslational modifications on the anticancer activity of Hsp90 inhibitors
- Mps1 mediated phosphorylation of Hsp90 confers renal cell carcinoma sensitivity and selectivity to Hsp90 inhibitors
- Synthesis and evaluation of new Hsp90 inhibitors based on a 1, 4, 5-trisubstituted 1, 2, 3-triazole scaffold
- Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/Hsp90 dual-targeted inhibitors
- Hsp90 inhibitors in lung cancer: promise still unfulfilled
- Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux
- Paralog specific Hsp90 inhibitors–a brief history and a bright future
- Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors
- Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
- Structural determination of three different series of compounds as Hsp90 inhibitors using 3D-QSAR modeling, molecular docking and molecular dynamics …
- Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity
- Development of heat shock protein (Hsp90) inhibitors to combat resistance to tyrosine kinase inhibitors through HSP90–kinase interactions
- Potent antitumor activity of the novel Hsp90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
- Discovery of potent N-(isoxazol-5-yl) amides as Hsp90 inhibitors
- Design, Synthesis, and Biological Evaluation of Conformationally Constrained cis-Amide Hsp90 Inhibitors
- IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma
- Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and Hsp90 inhibitors
- Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as Hsp90 C-terminal inhibitors
- … Conformational Dynamics between Plasmodium falciparum and Human Hsp90 Orthologues Enable the Structure-Based Discovery of Pathogen-Selective Inhibitors
- High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for Hsp90 inhibitors
- Principal component analysis on molecular descriptors as an alternative point of view in the search of new Hsp90 inhibitors
- Reversing drug resistance of cisplatin by Hsp90 inhibitors in human ovarian cancer cells
- Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as …
- Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors
- Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for …
- FBW7-dependent Mcl-1 degradation mediates the anticancer effect of Hsp90 inhibitors
- Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): synthesis, biology, and molecular modeling
- Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity
- Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy
- Hsp90 inhibitors attenuate effect of dexamethasone on activated NF-κB and AP-1
- Possible effects of early treatments of Hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs
- Synthesis and biological evaluation of novobiocin core analogues as Hsp90 inhibitors
- Heat shock protein 90 (Hsp90) inhibitors activate the heat shock factor 1 (HSF1) stress response pathway and improve glucose regulation in diabetic mice
- Synthesis and antiproliferative activity of novobiocin analogues as potential Hsp90 inhibitors
- High-throughput screen of natural product libraries for Hsp90 inhibitors
- Hsp90 inhibitors NVP-AUY922 and NVP-BEP800 may exert a significant radiosensitization on tumor cells along with a cell type-specific cytotoxicity
- Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss
- Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors
- Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo [2, 3-d] pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based …
- Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells
- Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel Hsp90 inhibitors
- Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action
- A potential role for Hsp90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry
- Development of noviomimetics as C-terminal Hsp90 inhibitors
- A large animal model to evaluate the effects of Hsp90 inhibitors for the treatment of lung adenocarcinoma
- Solution-phase parallel synthesis of Hsp90 inhibitors
- Molecular docking study, synthesis and biological evaluation of Schiff bases as Hsp90 inhibitors
- 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer
- Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors
- Use of Hsp90 inhibitors to disrupt GDI‐dependent Rab recycling
- … -mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1α destabilization by SH-1242 and SH-1280, novel Hsp90 inhibitors
- Practical synthesis of novel purine analogues as Hsp90 inhibitors
- Hsp90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells
- Novel Hsp90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion
- Asymmetric synthesis of pochonin E and F, revision of their proposed structure, and their conversion to potent Hsp90 inhibitors
- Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido [4, 3-d] pyrimidines core through shape-based screening
- Identification of limonol derivatives as heat shock protein 90 (Hsp90) inhibitors through a multidisciplinary approach
- An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors–potential therapeutics in cancer and neurodegeneration
- RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells
- Design and synthesis of 2-amino-6-(1H, 3H-benzo [de] isochromen-6-yl)-1, 3, 5-triazines as novel Hsp90 inhibitors
- Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors
- Breast cancer and Hsp90 inhibitors: is there a role beyond the HER2-positive subtype?
- HSP27 knockdown produces synergistic induction of apoptosis by Hsp90 and kinase inhibitors in glioblastoma multiforme
- Identification of new Hsp90 inhibitors by structure-based virtual screening
- Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs
- Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-
dihydroxyphenyl)-1, 2, 3-thiadiazole Hsp90 inhibitors - Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening
- Identification of a new series of potent diphenol Hsp90 inhibitors by fragment merging and structure-based optimization
- Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90
- The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors
- Design, synthesis and biological evaluation of 17-arylmethylamine-17-
demethoxygeldanamycin derivatives as potent Hsp90 inhibitors - An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma
- Hsp90 inhibitors, part 2: combining ligand-based and structure-based approaches for virtual screening application
- Client proteins and small molecule inhibitors display distinct binding preferences for constitutive and stress-induced Hsp90 isoforms and their …
- Hsp90 inhibitors disrupt a transient Hsp90-HSF1 interaction and identify a noncanonical model of Hsp90-mediated HSF1 regulation
- Hsp90 inhibitors, geldanamycin and radicicol, enhance fisetin-induced cytotoxicity via induction of apoptosis in human colonic cancer cells
- Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors
- Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis
- Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors.
- ER homeostasis and motility of NSCLC cell lines can be therapeutically targeted with combined Hsp90 and HDAC inhibitors
- Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1
- Synthesis and biological evaluation of 3, 5-disubstituted-4-
alkynylisoxozales as a novel class of Hsp90 inhibitors - Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC)
- Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity
- Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study
- Clinical evaluation and biomarker profiling of Hsp90 inhibitors
- ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system
- How selective are Hsp90 inhibitors for cancer cells over normal cells?
- … II study of Hsp90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors …
- Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-
demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90 - Redefining the phenotype of heat shock protein 90 (Hsp90) Inhibitors
- Multiclass comparative virtual screening to identify novel Hsp90 inhibitors: a therapeutic breast cancer drug target
- 2, 4-dihydroxy benzaldehyde derived Schiff bases as small molecule Hsp90 inhibitors: Rational identification of a new anticancer lead
- A computational analysis of pyrazole-based inhibitors binding to Hsp90 using molecular dynamics simulation and the MM-GBSA method
- Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis
- A novel class of small molecule inhibitors of Hsp90
- 4, 5, 6, 7-Tetrahydro-isoxazolo-[4, 5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors
- … and SAR study of N-(4-hydroxy-3-(2-
hydroxynaphthalene-1-yl) phenyl)-arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in … - Hsp90 inhibitors for the treatment of chronic myeloid leukemia
- Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins
- Virtual screening and biophysical studies lead to Hsp90 inhibitors
- Hsp90 inhibitors: a potential treatment for latent EBV infection?
- Biological evaluation of 3-acyl-2-arylamino-1, 4-naphthoquinones as inhibitors of Hsp90 chaperoning function
- Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular …
- HDAC and Hsp90 inhibitors down‐regulate PTTG1/securin but do not induce aneuploidy
- AKT kinase and Hsp90 inhibitors as novel anti-cancer therapeutics
- Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
- Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of Hsp90 inhibitors
- A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes
- Protection of oligodendrocyte precursor cells by low doses of Hsp90 inhibitors in cell culture
- Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (Hsp90)
- Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90
- Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors
- Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors
- Discovery of diamine-linked 17-aroylamido-17-
demethoxygeldanamycins as potent Hsp90 inhibitors - Ansamycin inhibitors of Hsp90: nature’s prototype for anti-chaperone therapy
- Design and synthesis of 3′, 5′-ansa-adenosines as potential Hsp90 inhibitors
- Reinventing Hsp90 Inhibitors: Blocking C‐Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors
- New dihydropyrimidin-2 (1 H)-one based Hsp90 C-terminal inhibitors
- Hsp90 inhibitors, part 1: definition of 3-D QSAutogrid/R models as a tool for virtual screening
- Combined pharmacophore and structure-guided studies to identify diverse Hsp90 inhibitors
- High cytotoxic sensitivity of the oligodendrocyte precursor cells to Hsp90 inhibitors in cell cultures
- Hsp90 inhibitors in oncology: ready for prime time?
- Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo [2, 3-d] pyrimidines as potent Hsp90 inhibitors
- Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors
- … and pharmacological evaluation of 4, 5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors
- The non-Geldanamycin Hsp90 inhibitors enhanced the antifungal activity of fluconazole
- Ligand desolvation steers on-rate and impacts drug residence time of heat shock protein 90 (Hsp90) inhibitors
- Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors
- Chemoproteomics-driven drug discovery: identification of novel Hsp90 inhibitors
- Dimeric and trimeric triazole based molecules as a new class of Hsp90 molecular chaperone inhibitors
- Design, synthesis, and structure activity relationships for chimeric inhibitors of Hsp90
- The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition
- Macrocyclic inhibitors of hsp90
- Hsp90 inhibitors decrease AID levels and activity in mice and in human cells
- Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites
- Discovery of Novel 17‐
Phenylethylaminegeldanamycin Derivatives as Potent Hsp90 Inhibitors - Proteolytic degradation of nitric oxide synthase: effect of inhibitors and role of Hsp90-based chaperones
- Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) Inhibitors
- A global view of the proteome perturbations by Hsp90 inhibitors
- Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (Hsp90) inhibitors
- Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors
- 2′‐O‐Alkyl Derivatives and 5′‐Analogues of 5‐Aminoimidazole‐4‐
carboxamide‐1‐β‐D‐ ribofuranoside (AICAR) as Potential Hsp90 Inhibitors - Effects of Hsp90 inhibitors, geldanamycin and its analog, on ceramide metabolism and cytotoxicity in PC12 cells
- Structure–activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity
- Identification of the key structural elements of a dihydropyrimidinone core driving toward more potent Hsp90 C-terminal inhibitors
- Design, synthesis, and anticancer activity of C8-substituted-4′-
thionucleosides as potential Hsp90 inhibitors - Discovery of novel Hsp90 inhibitors that induced apoptosis and impaired autophagic flux in A549 lung cancer cells
- Molecular docking study, synthesis and biological evaluation of Mannich bases as Hsp90 inhibitors
- Dynamics-based discovery of allosteric inhibitors: Selection of new ligands for the C-terminal domain of Hsp90
- Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitization
- Hsp90 inhibitors as senolytic drugs to extend healthy aging
- Design and synthesis of N-(5-chloro-2, 4-dihydroxybenzoyl)-(R)-1, 2, 3, 4-tetrahydroisoquinoline-3-
carboxamides as novel Hsp90 inhibitors - Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors
- An Improved Synthesis of Resorcylic Acid Macrolactone Inhibitors of Hsp90
- Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer
- Hsp90 inhibitors
- Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold
- 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of Hsp90 and HDAC
- Potentiation of Topoisomerase I inhibitors by Hsp90 inhibitors: Mechanistic and Functional studies
- Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not Hsp90 inhibitors in models of HER2 amplified breast cancer
- Correlation between crystal violet dissolution assay and manual colony counting on the In Vitro effects of Hsp90-inhibitors.
- Hsp90 inhibitors and the reduction of anti-cancer drug resistance by non-genetic and genetic mechanisms
- Stability of the human Hsp90-p50Cdc37 chaperone complex against nucleotides and Hsp90 inhibitors, and the influence of phosphorylation by casein kinase 2
- Design, synthesis and biological evaluation of 7-(aryl)-2, 3-dihydro-[1, 4] dioxino [2, 3-g] quinoline derivatives as potential Hsp90 inhibitors and anticancer agents
- Discovery of 5-substituted 2-amino-4-chloro-8-((4-
methoxy-3, 5-dimethylpyridin-2-yl) methyl)-7, 8-dihydropteridin-6 (5H)-ones as potent and selective Hsp90 inhibitors - Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC)
- Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities
- Hsp90 inhibitors alter capsaicin-and ATP-induced currents in rat dorsal root ganglion neurons
- Sensitization of multidrug-resistant cancer cells to Hsp90 inhibitors by NSAIDs-induced apoptotic and autophagic cell death
- Effects of Hsp90 binding inhibitors on sGC-mediated vascular relaxation
- Spontaneous assembly of Hsp90 inhibitors at water/octanol interface: A molecular dynamics simulation study
- Discovery of potent and selective CDK8 inhibitors from an Hsp90 pharmacophore
- Hsp90 inhibitors radicicol and geldanamycin have opposing effects on Leishmania Aha1-dependent proliferation
- Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors
- A group of novel HIF‐1α inhibitors, glyceollins, blocks HIF‐1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding
- Recent advances in macrocyclic Hsp90 inhibitors
- Identification of Hsp90 inhibitors with anti-Plasmodium activity
- 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold
- Computational predictions of corroles as a class of Hsp90 inhibitors
- Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening
- Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and Hsp90 inhibition
- New Indications for Hsp90 and HSP70 Inhibitors as Antiviral Drugs
- … study of the Hsp90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR …
- Crystallization and preliminary X-ray diffraction analysis of Trap1 complexed with Hsp90 inhibitors
- Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas …
- Lead identification: better Hsp90 inhibitors
- Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C‐terminal Inhibitors
- Triazole containing novobiocin and biphenyl amides as Hsp90 C-terminal inhibitors
- Recent progress in the study of Hsp90 inhibitors [J]
- Met amplification and Hsp90 inhibitors
- A novel pharmacodynamic assay to measure Hsp90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors
- Synthesis and evaluation of 4-(2-hydroxypropyl) piperazin-1-yl) derivatives as Hsp90 inhibitors
- Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (Hsp90)
- Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape‐Based Similarity Screening
- The Hsp90 Inhibitors, 17-aag and 17-dmag Target Wild-Type B-raf Signaling for the Proliferation of Human Uveal Melanoma Cells
- Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2, 4-diaminopyrimidine motifs
- Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST …
- Low-dose Hsp90 inhibitors DPB and AUY-922 repress apoptosis in HUVECs
- Hsp90 inhibitors in parasitic nematodes: prospects and challenges
- Preface [Hot topic: Hsp90 Molecular Chaperone Inhibitors: Opportunities and Challenges (Guest Editor: Paul Workman)]
- Combination therapies with Hsp90 inhibitors against colorectal cancer
- Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases
- Design and biological testing of peptidic dimerization inhibitors of human Hsp90 that target the C-terminal domain
- Hsp90 inhibitors suppress P53 phosphorylation in LPS-induced endothelial inflammation
- Evaluation of miscellaneous heat shock protein (Hsp90) inhibitors using different methodologies
- Hsp90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line
- Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors
- Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C‐Terminal Inhibitors
- Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors
- Synthesis of 5,6‐dihydro‐4H‐benzo[d]
isoxazol‐7‐one and 5,6‐dihydro‐4H‐isoxazolo[5,4‐ c]pyridin‐7‐one Derivatives as Potential Hsp90 Inhibitors - A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structure–activity relationships and anti-HCV activity in …
- New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting
- Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors
- Hsp90 inhibitors potentiate PGF2α-induced IL-6 synthesis via p38 MAP kinase in osteoblasts
- Combination of jak2 and Hsp90 inhibitors: An effective therapeutic option in drug-resistant chronic myelogenous leukemia
- Abstract# 1710: A novel pharmacodynamic assay to measure Hsp90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors
- Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain
- Study on the Hsp90 Inhibitors
- Combined in Silico and Experimental Approach for Drug Design: The Binding Mode of Peptidic and Non‐Peptidic Inhibitors to Hsp90 N‐Terminal Domain
- Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors
- Hsp90 inhibitors are promising radiosensitizers for radiotherapy
- Synthesis and biological evaluation of hybrid acridine-Hsp90 ligand conjugates as telomerase inhibitors
- … vitro study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble Hsp90 inhibitor, 17-AAG …
- Inhibitors of the Hsp90 C-terminus
- The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and …
- Reduction of benzoquinone ansamycin Hsp90 inhibitors by NQO1 generates hydroquinone ansamycins which are more potent Hsp90 inhibitors
- Investigation of B, C-ring truncated deguelin derivatives as heat shock protein 90 (Hsp90) inhibitors for use as anti-breast cancer agents
- Identifying inhibitors of the Hsp90-Aha1 protein complex, a potential target to drug cystic fibrosis, by alpha technology
- Combining ensemble learning with a fragment-based topological approach to generate new molecular diversity in drug discovery: In silico design of Hsp90 inhibitors
- Design, synthesis, and biological activities of vibsanin B derivatives: a new class of Hsp90 C-terminal inhibitors
- Progress in the study of small molecule inhibitors of HSP90
- Virtual Screening for Dual Hsp90/B-Raf Inhibitors
- Prediction of inhibitory activities of Hsp90 inhibitors
- New Hsp90 selective inhibitors as therapeutic agents for prostate and bladder cancer.
- 145 POSTER Hsp90 inhibitors target addiction to mutant oncoproteins in colorectal cancer
- 570 POSTER Overcoming resistance to tyrosine kinase inhibitors (TKls) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets …
- Towards ‘best-in-class’ Hsp90 inhibitors: Design, biosynthesis and pre-clinical profiles
- Evaluation of the effect of Hsp90 inhibitors on head and neck squamous cell carcinoma cell lines
- Mechanism of action of a novel series of inhibitors of the Hsp90 molecular chaperone
- Effects of Inhibitors on Hsp90′ s Conformational Dynamics, Cochaperone and Client Interactions
- Design and synthesis of imidazopyridine derivatives as novel Hsp90 inhibitors for the treatment of cancer
- Therapeutic Uses of Hsp90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)
- Development of a FRET-based high-throughput screening system for the discovery of Hsp90 inhibitors
- Histone deacetylase inhibitors interrupt HSP90• RASGRP1 and HSP90• CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells
- Inhibition of mTOR enhances the activity of Hsp90 inhibitors in part through cessation of heat shock protein synthesis.
- Hsp90 Flexibility and Development of its Inhibitors for the Treatment of Cancer
- Neuroprotective Features Of Hsp90 Inhibitors Exhibiting Anti-Inflammatory Actions: Implications For Multiple Sclerosis
- Integration of Hsp90 inhibitors in combinational immunotherapy targeting receptor tyrosine kinases (RTKs) in cancer (131.45)
- Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells
- … the in-silico design of new Hsp90 inhibitors: Molecular docking and 3D-QSAR CoMFA studies of tetrahydropyrido [4, 3-d] pyrimidine derivatives as Hsp90 inhibitors
- Hsp90 inhibitors stimulate DNAJB4 protein expression through a mechanism involving N 6-methyladenosine
- Hsp90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways
- Structural and energetic insight into the isoform-selective inhibitors of tumour marker Hsp90 against Grp94
- In vitro and in vivo Evaluation of 17-phenylpropylamine/
phenoxyethylamine-17- demethoxygeldanamycins as Potent Hsp90 Inhibitors - Suppression by Hsp90 inhibitors of BMP‑4‑stimulated osteoprotegerin synthesis in osteoblasts: Attenuation of p70 S6 kinase
- Synthesis and evaluation of the tumor cell growth inhibitory potential of new putative Hsp90 inhibitors
- Drug metabolism determines resistance of colorectal cancer to resorcinol-based Hsp90 inhibitors
- The importance of dose schedule with Hsp90 inhibitors: Results from a Phase II study in dogs with mast cell tumors.
- Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants
- New heat shock protein (Hsp90) inhibitors, designed by pharmacophore modeling and virtual screening: synthesis, biological evaluation and molecular dynamics …
- C-Terminal Hsp90 Inhibitors Block the HIF-1 Hypoxic Response by Degrading HIF-1α through the Oxygen-Dependent Degradation Pathway
- Prediction of new Hsp90 inhibitors based on 3, 4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation
- A potential role for NAD (P) H: quinone oxidoreductase 1 (NQO1) in the mechanism of action of the Hsp90 inhibitors geldanamycin and 17AAG
- Dorsomorphin induces cancer cell apoptosis and sensitizes cancer cells to Hsp90 and proteasome inhibitors by reducing nuclear heat shock factor 1 levels
- Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor …
- Correction: Identification of the key structural elements of a dihydropyrimidinone core driving toward more potent Hsp90 C-terminal inhibitors
- … and pharmacological evaluation of N-(5-chloro-2, 4-dihydroxybenzoyl)-(R)-N-
arylmethyl-1, 2, 3, 4-tetrahydro-3- isoquinolinecarboxamides as potent Hsp90 inhibitors - Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain
- Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors
- Overcoming Resistance to Small Molecule Kinase Inhibitors (SMKIs) Through Inhibition of Heat Shock Protein 90 (Hsp90) Chaperone Function in Patients with …
- Investigation of the Hsp90 C-terminal binding site, novel inhibitors and isoform-dependent client proteins
- Hsp90 inhibitors and conjunctival melanoma
- Potentials of Hsp90 Inhibitors in Cancer Therapy. pdf
- Development of Novel Inhibitors of HSP90
- Natural product inspired Hsp90 inhibitors
- A New Generation of Isoform Selective Hsp90 Inhibitors: Targeting the Cytosolic Hsp90 Isoforms
- Circumventing Hsp90 inhibitors via apoptosis block
- A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors
- QS288. Potent Blockade of TGF-β Signaling by Hsp90 Inhibitors
- Hsp90 inhibitors for high-grade glioma treatment
- A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
- The role of NQO1 in the metabolism of benzoquinone ansamycin Hsp90 inhibitors and development of novel Hsp90 inhibitors as anticancer agents
- Structure-based drug discovery of species-selective inhibitors of Hsp90
- Potent non-benzoquinone ansamycin Hsp90 inhibitors from mutasynthesis
- Targeting oncogenic Eph receptor proteins with Hsp90 inhibitors
- Client depletion assay comparison of paclitaxel to Hsp90 inhibitors
- Hsp90 Inhibitors in Sepsis and Sepsis-induced Acute Lung Injury
- 19-Substituted benzoquinone ansamycin Hsp90 inhibitors: Effects on Hsp90 co-chaperones and Hsp90-Hsf1 complexes in cellular systems
- In Vitro Dual Treatment of Cancer Cells with Hsp90 Inhibitors and Hyperthermia
- Recent Advances in the Discovery of Novel Hsp90 Inhibitors: An Update from 2014.
- Abstract# 3697: Combination of Hsp90 inhibitors and MEK inhibitors abrogates ERK activation in pancreatic cancer cells
- Targeting basal-like breast cancer via purine-scaffold Hsp90 inhibitors
- C-terminal Hsp90-inhibitors restore glucocorticoid sensitivity in Cushing’s disease
- Development of Hsp90 paralog specific inhibitors with mitochondrial drug delivery system
- Use of Hsp90 inhibitors in the combination immunotherapy of melanoma (P4272)
- Abstract# 915: Cystine/glutamate transporter SLC7A11 mediates resistance to Hsp90 inhibitors
- Proteomic Profiling of Hsp90 Inhibitors
- Synthetic Hsp90 inhibitors are active against 17-AAG-resistant tumor lines
- Acquired resistance to Hsp90-inhibitors and cancer progression
- Profiling Hsp90 inhibitors in cellular extracts on a mass spectrometry chemoproteomics platform
- 19-Substituted benzoquinone ansamycins. Hsp90 inhibitors with decreased off-target toxicity
- Barrier-protective effects of Hsp90 inhibitors in bovine pulmonary arterial endothelial cells.
- Hsp90 Inhibitors in Clinic
- Synthesis and exploration of resorcinol derivatives as Plasmodium falciparum Hsp90 inhibitors
- Inhibitors of Hsp90 in melanoma
- Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity
- Verification of a multivariate pharmacodynamic biomarker assay for Hsp90 inhibitors
- MP05-16 TSC1 EXPRESSION AS A PREDICTIVE BIOMARKER OF BLADDER CANCER RESPONSE TO Hsp90 INHIBITORS
- Computational modeling of the Hsp90 interactions with cochaperones and Small-Molecule inhibitors
- Hsp90 inhibitors: Biosynthetic and antitumor evaluation of a non-geldanamycin polyketide
- Hsp90 Inhibitors as New Leads To Target
- Development of a multivariate pharmacodynamic biomarker assay for Hsp90 inhibitors
- Abstract C86: Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.
- Correlation between in vitro and in vivo activities of Hsp90 inhibitors
- Hsp90 inhibitors target KRAS mutant human tumors through degradation of STK33
- Application of Hsp90 inhibitors to treat chronic lymphocytic leukemia by targeting the BCR-NFκB pathway
- Effect of 19-substituted benzoquinone ansamycin Hsp90 inhibitors on Hsp90/Cdc37/co-chaperone complexes and casein kinase 2 (CK2) activity
- Discovery of novel small molecule inhibitors of Hsp90 for oral treatment
- Synergistic inhibition of cancer cell viability and suppression of HIF1α by CDK4 inhibitors and Hsp90 inhibitors across cancer types
- Silencing of the heat shock protein 90 (Hsp90) cochaperone CDC37 by RNA interference sensitises cancer cells to Hsp90 inhibitors
- Discovery of N‐pyridoyl‐Δ2‐pyrazolines as Hsp90 inhibitors
- Hsp90 inhibitors as a future therapeutic strategy in diabetes-driven atherosclerosis.
- 555 POSTER Small-molecule inhibitors of Hsp90 in IM-resistant gastrointestinal stromal tumors
- Anti-tumor activity of non-benzoquinone ansamycin Hsp90 inhibitors in murine xenograft models
- C-terminal Hsp90 inhibitors restore glucocorticoid sensitivity in an experimental model for Cushing’s disease
- Abstract B36: Targeting BRCA1 through natural Hsp90 inhibitors to reverse platinum resistance in TNBC
- Efficacy of the Hsp90 Inhibitors in Prostate Cancer Therapy
- Potent anti-inflammatory activity of a novel of class Hsp90 inhibitors for multiple sclerosis (51.1)
- Potential of Hsp90 Inhibitors to Treat Neurofibromatosis-Related Tumors
- Screening of miscellaneous Hsp90 inhibitors using virtual co-crystallized pharmacophore
- Design, synthesis and biological evaluation of ansamycin prodrugs as water-soluble Hsp90 inhibitors
- Role of Hsp90 Inhibitors in the Treatment of Cancer
- A high-throughput screen for inhibitors of the Hsp90-chaperone machine
- Small-molecule Hsp90 Inhibitors: Applications in Cancer and Neurodegenerative diseases
- Anti-cancer effect by combination treatment of CDK and Hsp90 inhibitors through HIF1α inhibition
- C-terminal Hsp90 Inhibitors Block the HSP90: HIF-1a Interaction and Inhibit the Cellular Hypoxic Response
- p23/Sba1p protects against Hsp90 inhibitors
- N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression
- PHARMACOPHORIC MODEL AND 3D-QSAR OF 5-RESORCINOL-ISOXAZOLE DERIVATIVES AS Hsp90 INHIBITORS
- Abstract# 4688: Hsp90 inhibitors downregulate the VEGF excretion in triple negative breast cancer cells
- Rational Identification of Hsp90 Inhibitors as Anticancer Lead Molecules by Structure Based Drug Designing Approach.
- P2-384: In vivo effects of novel Hsp90 C-terminal inhibitors in Tau mutant mice
- In vivo antitumor efficacy of purine-scaffold Hsp90 inhibitors in basal-like breast cancer (BLBC)
- 19P Comparative effectiveness analysis of Hsp90 inhibitors in non-small cell lung cancer
- Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by Hsp90 inhibitors
- The Potential Dual-Target Inhibitors for HER2/Hsp90 Proteins from Traditional Chinese Medicine
- Development of a cell-based ligand-screening system for identifying Hsp90 inhibitors
- Precursor-directed biosynthesis of macbecin analogues: generation of non-quinone containing Hsp90 inhibitors and pre-clinical evaluation
- Selective inhibition of Hsp90 by its C-terminal inhibitors is more effective to suppress bladder cancer cell growth
- Hsp90 inhibitors prevent LPS-induced endothelial barrier dysfunction by disrupting RhoA signaling.
- Hsp90 inhibitors prevent LPS-induced endothelial hyper-permeability by inhibiting pp60src activation and maintaining adherens junction proteins
- Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures
- Discovery of Hsp90 Inhibitors from Natural Product and Its Analogues
- Effects of Hsp90 inhibitors on triple-negative breast cancer: BRCA1 as a therapeutic target for TNBC
- AB035. P006. Activity of heat shock protein-90 (Hsp90) inhibitors against pancreatic cancers grown in 3 dimensions
- Cover Feature: Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C‐Terminal Inhibitors (ChemMedChem 24/2017)
- Combination use of natural Hsp90 inhibitors to reverse BRCA1-mediated platinum resistance in triple negative breast cancer
- Hsp90 inhibitors induce the unfolded protein response in bovine and mice lung cells
- A detailed analysis of protein binding and biological activity of methoxy-substituted resorcinylic isoxazole amide Hsp90 inhibitors
- Fe3O4 nanoparticles mediated synthesis of novel spirooxindole‐
dihydropyrimidinone molecules as Hsp90 inhibitors - A genome-wide CRISPR/Cas9 pooled screen identifies EML4-ALK variant-specific synthetic lethal partners of Hsp90 inhibitors
- Discovery of Heat Shock Protein 90 (Hsp90) Inhibitors against Cancerous Diseases
- Cell cycle control and apoptosis of p53-isogenic cell lines treated with Hsp90 inhibitors
- Novel Hsp90 inhibitors exhibiting in vivo xenograft activity discovered using fragment-based drug discovery & structure based drug design.
- Targeting Hsp90 with small molecule inhibitors induces the overexpression of the anti-apoptotic molecule, survivin, in human cancer cells
- Discovery of Novel Hsp90 Inhibitors and Evaluation of Their Antitumor Activities
- Differential sensitivities to heat shock protein 90 (Hsp90) inhibitors in anaplastic lymphoma kinase (ALK)-positive non-small cell ling cancer (NSCLC) cells.
- Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors
- Design, Synthesis, and Evaluation of Site-Specific Hsp90 Inhibitors
- Abstract B102: 19-Substituted benzoquinone ansamycins: Decreasing the toxicity of the benzoquinone ansamycin class of Hsp90 inhibitors.
- Real-time imaging of disruption of human heat shock protein 90/co-chaperone p23 interactions by Hsp90 inhibitors in living subjects
- Hsp90 Inhibitors Blocking Multiple Oncogenic Signaling Pathways for the Treatment of Cancer
- Development of Hsp90 Inhibitors for the Treatment of HER-2 Positive Solid Cancers
- Discovery of Hsp90 inhibitors form natural product and its analogues
- Rational synthesis and evaluation of IMP dehydrogenase and Hsp90 inhibitors
- Abstract# 4677: NVP-BEP795 and NVP-BEP800: Novel, fragment derived orally bioavailable small molecule Hsp90 inhibitors with potent antitumor activity
- Ansamycin Class of Natural Product Hsp90 Inhibitors
- Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies
- … OF Hsp90 SUBPOPULATION CONFORMATIONS TARGETED BY INHIBITORS AND THE EFFECT OF PHOSPHORYLATION ON HSP90’S ASSOCIATION WITH CO …
- HSP70 and Hsp90 Inhibitors Repress Expression of TSC1 in T24 Bladder Cancer Cells and UOK139, UOK 140 Kidney Cancer Cells
- Identification of the correlation between drug activity and sensitivity of Hsp90 inhibitors in breast cancer cells using a multivariate gene expression assay
- Proteomic Analysis of Hct116 Colon Cancer Cells Treated with Inhibitors That Bind to the N-terminal Versus the C-terminal Domain of Hsp90
- Differential Sensitivities of Human Multidrug-resistant Cancer Cells to BIIB021 and Modulation of Hsp90 Inhibitors by NSAIDs and Niclosamide
- Design of Novel Hsp90 Inhibitors to Trigger Tau Degradation in Alzheimer’s disease: An Insilico Approach
- Assessing efficacy of novel Hsp90 inhibitors in breast cancer patients by enumeration of circulating tumor cells and HER-2 degradation
- Hsp90 inhibitors diminish PDGF-BB-induced migration of osteoblasts via suppression of p44/p42 MAP kinase
- Identification and Structure-Activity Studies of 1, 3-Dibenzyl-2-aryl imidazolidines as Novel Hsp90 Inhibitors
- Design, synthesis, and molecular docking studies of novel pyrazolyl 2‐aminopyrimidine derivatives as Hsp90 inhibitors
- 281P Selective depletion of tumour-associated SAMHD1 by Hsp90 inhibitors enhances the anti-AML effect of cytarabine
- Insights into the molecular mechanism of Hsp90 binding of methoxy-substituted resorcinylic isoxazole amide inhibitors reveal different isoform selectivity profiles
- Hch1p Acts Differently From Its Homologue, Aha1p, in Regulating Sensitivity of Hsp90 to Hsp90 Inhibitors in Yeast
- Ddis-12. Cyto-mito™-A Novel Class Of Dual-acting Hsp90 Inhibitors For The Treatment Of Glioblastoma
- Hsp90 inhibitors: their effects on redox status and on the cytoarchitecture
- Trth-03. Cyto-mito™-A Novel Class Of Dual-acting Hsp90 Inhibitors For The Treatment Of Glioblastoma
- Development of Tethered Hsp90 Inhibitors Carrying Radioiodinated Probes to Specifically Discriminate and Kill Malignant Breast Tumor Cells
- Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and Hsp90 Inhibitors
- Abstract PR05: Effects of Hsp90 inhibitors on triple-negative breast cancer: Notch as a therapeutic target for stem cells
- Reduction of a series of benzoquinone ansamycin Hsp90 inhibitors by one and two electron reductases, and their interaction with reduced glutathione
- Design and synthesis of fungal-selective resorcylate aminopyrazole Hsp90 inhibitors
- Abstract B018: A high-throughput screen identifies Hsp90 inhibitors as potent therapeutics across multiple clinically representative organoid models of advanced …
- Hsp90 Inhibitors Suppress Aryl Hydrocarbon Receptor-Mediated Activation of CYP1A1 and CYP1B1 Transcription and DNA Adduct Formation
- Medium-Throughput Detection of Hsp90/Cdc37 Protein–Protein Interaction Inhibitors Using a Split Renilla Luciferase-Based Assay
- Decoupling the mechanism of action of efrapeptins, dual inhibitors of proteasome and Hsp90 chaperone function: The possible role of endoplasmic reticulum stress
- Structure-based drug design of Hsp90 inhibitors and evaluation of their biological activities
- A New Generation of Hsp90 Inhibitors: Addressing Isoform Selectivity and Heat Shock Induction
- USE OF Hsp90 INHIBITORS TO OVERCOME TRASTUZUMAB RESISITANCE IN THE MINOR VARIANT OF HER2 P95HER2 IN BREAST CANCER
- Abstract# 4676: A novel class of specific Hsp90 small molecular inhibitors demonstrate in vitro and in vivo anti-tumor activity in the human melanoma cells
- A computational study on the role of water and conformational fluctuations in Hsp90 in response to inhibitors
- Hsp90 and Its Inhibitors for Cancer Therapy: Use of Nano-delivery System to Improve Its Clinical Application
- Identification and synthesis of 3, 4-isoxazolediamides as new class of Hsp90 inhibitors.
- Enhanced MHC Class I and II expression induced following staggered combination treatment of human tumor cells with Hsp90 inhibitors and Interferons.(165.16)
- 31 Structure-based drug design of Hsp90 inhibitors and their anti-proliferative effects against cancerous diseases
- … 90 (Hsp90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors
- Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
- 35P Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models
- Discovery of 2-((4-resorcinolyl)-5-aryl-1, 2, 3-triazol-1-yl) acetates as potent Hsp90 inhibitors with selectivity over TRAP1
- Molecular docking studies investigating the interaction of a series of benzoquinone ansamycin Hsp90 inhibitors with NAD (P) H: quinone oxidoreductase 1 (NQO1)
- Proteomics Fingerprints of Auy922 and 17-dmag Indicate Common Mechanisms of Action for Hsp90 Inhibitors
- Amide-tethered quinoline-resorcinol conjugates as a new class of Hsp90 inhibitors suppressing the growth of prostate cancer cells
- Synthesis Of Substituted Pyrrolo [2, 3-D] Pyrimidines As Microtubule-Binding Agents and Hsp90 Inhibitors
- The Pursuit of Unshocking Hsp90 Inhibitors: Development of Gedunin and Cruentaren A as Chemical Leads
- Discovery of 5-aryl-3-thiophen-2-yl-1H-
pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma - Hsp90 Inhibitors Prevent NF-κB-Dependent Gene Activation In Human Lung Microvascular Endothelial Cells By Inducing MDM2-Dependent Sirt-2-Promoter Binding
- … expression profiling highlights modulation of chromatin-related proteins and chromatin-modifying enzymes in response to Hsp90 inhibitors: Identification of PRMT5 …
- Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (Hsp90) inhibitors with significant anti-HIV activity
- Improving the Hsp90 Inhibitors Containing 4-(2, 4-Dihydroxyphenyl)-1, 2, 3-thiadiazole Scaffold: Synthesis, Affinity and Effect on Cancer Cells
- … vitro study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble Hsp90 inhibitor, 17-AAG …
- Hybrids of the Benzofuran Core from Natural Products and the 2, 4‐Dihydroxy‐5‐isopropylbenzene Fragment as Potent Hsp90 Inhibitors: Design, Synthesis and …
- High-throughput screens identify Hsp90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer
- … : Validation of a multiplex method for detection of several oncosignaling proteins with potential utility for assessment of pharmacodynamic activity of Hsp90 inhibitors
- … Ca2+-sensitivity from troponin I phosphorylation by hypertrophic and dilated cardiomyopathy mutations can be reversed by EGCG and related Hsp90 inhibitors
- … of truncated tau protein in transgenic rat cortical neurons and human cellular model of tauopathy and Alzheimer’s disease is enhanced by Hsp90 inhibitors
- … Discovery and Optimization of 4, 5-Diarylisoxazoles as Potent Dual Inhibitors of Pyruvate Dehydrogenase Kinase (PDHK) and Heat Shock Protein 90 (Hsp90)
- Design, synthesis and molecular mechanisms of novel dual inhibitors of heat shock protein 90/phosphoinositide 3-kinase alpha (Hsp90/PI3Kα) against cutaneous …
- … abstract Synthesis of 5, 6-dihydro-4H-benzo [d] isoxazol-7-one and 5, 6-dihydro-4H-isoxazolo [5, 4-c] pyridin-7-one derivatives as potential Hsp90 inhibitors
- … analogue (HA) histone deacetylase (HDAC) inhibitors (HDIs)-induced apoptosis: New role of HDAC6 inhibition, acetylation and inhibition of Hsp90 and depletion of …
- Patent application title: USES OF LABELED Hsp90 INHIBITORS Inventors: Gabriela Chiosis (New York, NY, US) Gabriela Chiosis (New York, NY, US) Tony …
- Proteasome Inhibitors Suppress ErbB Family Expression through Hsp90-Mediated Lysosomal Degradation
- Targeting Hsp90 chaperone machinery with small molecule inhibitors
- Targeting both ends of Hsp90: Chimeric N-terminal inhibitors and novobiocin-derivatized C-terminal inhibitors
- The Development of Organelle-localized Hsp90 Isoform-selective Inhibitors
- Design of potential Hsp90 and HDAC6 dual inhibitors: virtual screening on Hsp90.
- Sensitization of cancer cells to inhibitors of heat shock protein 90 (Hsp90) and proteasome by abamectin
- Synthetic and computational efforts toward the understanding and development of novobiocin-derived inhibitors of Hsp90
- Design and prediction of new inhibitors of Hsp90 by Virtual Screening
- Understanding conformational diversity of heat shock protein 90 (Hsp90) and binding features of inhibitors to Hsp90 via molecular dynamics simulations
- Design, Synthesis and Biological Evaluation of Ring-constrained and Biphenyl Derivatives as Hsp90 C-terminal Inhibitors
- Unfolding the Hsp90 Foldasome: Structure-Activity Relationship Studies on EGCG and Development of Isoform-Selective Inhibitors
- In silico identification and analysis of the binding site for aminocoumarin type inhibitors in the C-terminal domain of Hsp90
- Regulation of Calcineurin Signaling Through Blocking of the Chaperone Function of Hsp90 by HDAC Inhibitors
- In silico analysis of human Hsp90 for the identification of novel anti-cancer drug target sites and natural compound inhibitors
- Impressive Enrichment of Semiempirical Quantum Mechanics‐Based Scoring Function: Hsp90 Protein with 4541 Inhibitors and Decoys
- Blocking the protein folding machinery. Rational design of inhibitors of the molecular chaperone Hsp90 as new anticancer agents
- Hsp90 Binding Inhibitors Improve Survival and Attenuate the Inflammatory Insult in a Murine Model of Sepsis-Induced Acute Lung Injury.
- … OF Hsp90 IMPAIRS DNA-DAMAGE RESPONSE PROTEINS AND INCREASES THE SENSITIVITY OF OVARIAN CARCINOMA CELLS TO PARP INHIBITORS
- Direct and Indirect Modulation of EGFR-Mediated Growth Signaling by Hsp90 Inhibition in NSCLCs Resistant to EGFR Tyrosine Kinase Inhibitors in vitro and in vivo
- In silico identification of potent inhibitors of heat shock protein 90 (Hsp90) from Indonesian natural product compounds as a novel approach to treat ebola virus …
- Retraction notice to”” A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells””.
- … Study of the Hsp90 Inhibitor SNX-5422 and Erlotinib in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
- Synthesis of Truncated C8-Modified-4′-thionucleosides as Potential Hsp90 Inhibitors
- Development of novel Hsp90 inhibitors as potential anticancer agents
- HDAC and Hsp90 Inhibitors Down-Regulate PTTG1 / Securin But Do Not Induce Aneuploidy
- Stereoselective C, C coupling reactions for the total synthesis of the Hsp90 inhibitor geldanamycin
- Preclinical studies on the effectiveness of the new Hsp90 – inhibitor AUY922 alone and in combination with the BCR-ABL inhibitor imatinib for …
- Hsp90 inhibitors potentiate PGF2α-induced IL-6 synthesis via p38 MAP kinase in osteoblasts (骨 芽 細胞 に お い てHSP90阻 害 剤 は p38 MAP kinase を 介 し て…
- Combined Molecular Modeling Studies of Hsp90 Chaperone Inhibitors by Pharmacophore Model, Molecular Docking and 3D-QSAR
- Synergistic therapeutic effect of the combination of the Hsp90 inhibitor AUY922 and the PI3K inhibitor BYL719 with everolimus in neuroendocrine tumors
- A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
- 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration
- RACK1 competes with Hsp90 for binding to HIF-1α and is required for O2-independent and Hsp90 inhibitor-induced degradation of HIF-1α
- Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
- A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells
- Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin results in cytostasis and apoptosis - The Hsp90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms
- STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
- Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents
- 4-Amino derivatives of the Hsp90 inhibitor CCT018159
- The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy
- (−)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor
- A non-toxic Hsp90 inhibitor protects neurons from Aβ-induced toxicity
- NVP-AUY922: a small molecule Hsp90 inhibitor with potent antitumor activity in preclinical breast cancer models
- Silencing of Hsp90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17 …
- 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with Hsp90 inhibitor NVP-AUY922
- Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
- The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
- A rhizosphere fungus enhances Arabidopsis thermotolerance through production of an Hsp90 inhibitor
- Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structure− activity relationships
- Gambogic acid, a natural product inhibitor of Hsp90
- A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas
- Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin - Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with Hsp90 inhibitor and glycolysis inhibitor
- Total synthesis of the Hsp90 inhibitor geldanamycin
- CUDC-305, a novel synthetic Hsp90 inhibitor with unique pharmacologic properties for cancer therapy
- Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma
- Combination mammalian target of rapamycin inhibitor rapamycin and Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin has synergistic activity in multiple … - Targeting KRAS-mutant non–small cell lung cancer with the Hsp90 inhibitor ganetespib
- First-in-human phase I dose-escalation study of the Hsp90 inhibitor AUY922 in patients with advanced solid tumors
- Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors
- Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab
- Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-
17-demethoxygeldanamycin - 89Zr-trastuzumab PET visualises HER2 downregulation by the Hsp90 inhibitor NVP-AUY922 in a human tumour xenograft
- Derrubone, an inhibitor of the Hsp90 protein folding machinery
- Phase II study of the Hsp90-inhibitor BIIB021 in gastrointestinal stromal tumors
- Efficacy of the Hsp90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
- The novel Hsp90 inhibitor STA-9090 exhibits activity against Kit-dependent and-independent malignant mast cell tumors
- Functional characterization of the biosynthesis of radicicol, an Hsp90 inhibitor resorcylic acid lactone from Chaetomium chiversii
- Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
- BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy
- Mechanistic evaluation of the novel Hsp90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma
- Concise synthesis of pochonin A, an Hsp90 inhibitor
- Hsp90 chaperone inhibitor 17-AAG attenuates Aβ-induced synaptic toxicity and memory impairment
- Hsp90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way
- Analysis of expression of heat shock protein-90 (Hsp90) and the effects of Hsp90 inhibitor (17-AAG) in multiple myeloma
- Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17‐AAG)
- Identification and initial SAR of silybin: an Hsp90 inhibitor
- Molecular characterization of macbecin as an Hsp90 inhibitor
- BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance
- Potentiation of paclitaxel activity by the Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated … - The Hsp90 inhibitor, 17‐AAG, prevents the ligand‐independent nuclear localization of androgen receptor in refractory prostate cancer cells
- … isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90β generates sensitivity to the Hsp90 inhibitor …
- The Hsp90 inhibitor NVP-AUY922 potently inhibits non–small cell lung cancer growth
- Hsp90 inhibitor 17-AAG selectively eradicates lymphoma stem cells
- Ganetespib (STA-9090), a nongeldanamycin Hsp90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non–small cell lung cancer
- Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer
- The novel Hsp90 inhibitor STA‐1474 exhibits biologic activity against osteosarcoma cell lines
- Celastrol, a novel Hsp90 inhibitor, depletes Bcr–Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation
- Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
- Hsp90 inhibitor–mediated disruption of chaperone association of atr with Hsp90 sensitizes cancer cells to DNA damage
- Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1
- Hsp90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair
- Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling
- 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation
- Chemical proteomics-driven discovery of oleocanthal as an Hsp90 inhibitor
- Discovery of a novel Hsp90 inhibitor by fragment linking
- 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the Hsp90 inhibitor NVP-AUY922 in metastatic breast cancer patients
- Antitumor activity of the combination of an Hsp90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
- Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs
- ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the Hsp90 inhibitor geldanamycin.
- Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model
- An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
- Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells
- Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly (ethylene glycol)-b-poly (ε-caprolactone) micelles
- BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience
- Phase II trial of the Hsp90 inhibitor tanespimycin (Tan)+ trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
- A novel Hsp90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis
- The Hsp90 inhibitor radicicol interacts with the ATP-binding pocket of bacterial sensor kinase PhoQ
- Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells
- Nano self-assembly of recombinant human gelatin conjugated with α-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery
- mTOR inhibition potentiates Hsp90 inhibitor activity via cessation of HSP synthesis
- Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models - The Hsp90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
- Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges
- Opposite effects of the Hsp90 inhibitor Geldanamycin: induction of apoptosis in PC12, and differentiation in N2A cells
- Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1
- The Hsp90 inhibitor, AT13387, is effective against imatinib-sensitive and-resistant gastrointestinal stromal tumor models
- Second-generation Hsp90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells
- The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo
- The Hsp90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and-resistant MET-driven tumor models
- Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol
- A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in …
- AUY922, a novel Hsp90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.
- Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation
- Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer
- A C-terminal Hsp90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease
- SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells
- Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
- Non-invasive MRI tumor imaging and synergistic anticancer effect of Hsp90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model
- The Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition - Preclinical activity profile and therapeutic efficacy of the Hsp90 inhibitor ganetespib in triple-negative breast cancer
- Hsp90 inhibitor as a sensitizer of cancer cells to different therapies
- Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer
- Phase I/II study of Hsp90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine …
- Phase II study of the Hsp90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).
- Chemically accessible Hsp90 inhibitor that does not induce a heat shock response
- Proteome‐wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells
- The Hsp90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage
- A novel C-terminal Hsp90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells
- Hsp90 inhibitor encapsulated photo-theranostic nanoparticles for synergistic combination cancer therapy
- Inhibition of gastric tumor growth by a novel Hsp90 inhibitor
- The Hsp90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression
- Targeting Hsp90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer
- The Hsp90 inhibitor geldanamycin abrogates colocalization of eIF4E and eIF4E-transporter into stress granules and association of eIF4E with eIF4G
- Natural product Kongensin A is a non-canonical Hsp90 inhibitor that blocks RIP3-dependent necroptosis
- Phase I evaluation of STA-1474, a prodrug of the novel Hsp90 inhibitor ganetespib, in dogs with spontaneous cancer
- An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
- Why is this effective Hsp90 inhibitor not being developed in HER2+ breast cancer?
- The anti-myeloma activity of a novel purine scaffold Hsp90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
- Antitumor effect of novel Hsp90 inhibitor NVP-AUY922 against oral squamous cell carcinoma
- Synergistic action of the novel Hsp90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
- The effects of an Hsp90 inhibitor on the paradoxical effect
- A phase I study of the Hsp90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas
- Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the Hsp90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma
- Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of Hsp90 inhibitor geldanamycin
- A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation
- First-in-human phase I dose escalation study of a second-generation non-ansamycin Hsp90 inhibitor, AT13387, in patients with advanced solid tumors
- P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin on human oral squamous cell carcinoma cell lines - Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
- Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context
- Hsp90 inhibitor 17‐AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance
- The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in …
- Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts
- High-content, high-throughput analysis of cell cycle perturbations induced by the Hsp90 inhibitor XL888
- Geldanamycin, a Hsp90 inhibitor, attenuates the hypoxia-induced vascular endothelial growth factor expression in retinal pigment epithelium cells in vitro
- The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme
- Combination therapy with Hsp90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells
- Apoptosis caused by Hsp90 inhibitor geldanamycin in Leishmania donovani during promastigote-to-amastigote transformation stage
- Identification of the plant compound geraniin as a novel Hsp90 inhibitor
- The Novel Hsp90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations
- Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol
- Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1
- Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11
- Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells - Synthesis and structure–activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor
- Stage 1 testing and pharmacodynamic evaluation of the Hsp90 inhibitor alvespimycin (17‐DMAG, KOS‐1022) by the pediatric preclinical testing program
- Mode of cell death induced by the Hsp90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX
- ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation
- The Hsp90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments
- Hsp90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells
- Phase I trial of the Hsp90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies
- Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer
- The co-chaperone Hch1 regulates Hsp90 function differently than its homologue Aha1 and confers sensitivity to yeast to the Hsp90 inhibitor NVP-AUY922
- Targeting GRP75 improves Hsp90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma
- Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells
- Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS)
- Recent updates on the development of ganetespib as a Hsp90 inhibitor
- SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells
- Total synthesis of resorcinol amide Hsp90 inhibitor AT13387
- A novel pulse-chase SILAC strategy measures changes in protein decay and synthesis rates induced by perturbation of proteostasis with an Hsp90 inhibitor
- Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomas
- Hsp90 inhibitor celastrol reinstates growth plate angiogenesis in thiram-induced tibial dyschondroplasia
- Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90
- Novel Hsp90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells
- A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
- Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an Hsp90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer.
- The Hsp90 inhibitor ganetespib radiosensitizes human lung adenocarcinoma cells
- Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non–small cell lung cancer
- Anti‐myeloma activity of the novel 2‐aminothienopyrimidine Hsp90 inhibitor NVP‐BEP800
- Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer
- A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.
- Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model
- Molecular signature of response and potential pathways related to resistance to the Hsp90 inhibitor, 17AAG, in breast cancer
- The Hsp90 inhibitor 17-allylamide-17-
demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down … - Effectively delivering a unique Hsp90 inhibitor using star polymers
- Synthesis of Hsp90 inhibitor dimers as potential antitumor agents
- Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia
- Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular …
- The Hsp90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
- Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
- A purine scaffold Hsp90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB
- Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer
- Pre-clinical efficacy of PU-H71, a novel Hsp90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma
- Presence of MLH1 protein aggravates the potential of the Hsp90 inhibitor radicicol to sensitize tumor cells to cisplatin
- Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib
- BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
- Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the Hsp90 inhibitor ganetespib
- The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress
- Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake
- Phase I dose-escalation study of the Hsp90 inhibitor AUY922 in Japanese patients with advanced solid tumors
- Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms
- Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition
- Hsp90 inhibitor geldanamycin increases hsp70 mRNA stabilisation but fails to activate HSF1 in cells exposed to hydrostatic pressure
- Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922
- Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90
- Hsp90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and Hsp90 signaling network complex in leukemia cells
- BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway
- Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemia …
- Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib
- Radicicol, an Hsp90 inhibitor, inhibits intestinal inflammation and leakage in abdominal sepsis
- Hsp90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors
- Combining an Hsp70 inhibitor with either an N-or C-terminal Hsp90 inhibitor produces mechanistically distinct phenotypes
- Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation
- The novel Hsp90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells
- Protection of murine neural progenitor cells by the Hsp90 inhibitor 17‐allylamino‐17‐
demethoxygeldanamycin in the low nanomolar concentration range - Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma
- The apoptotic effect and associated signalling of Hsp90 inhibitor 17‐DMAG in hepatocellular carcinoma cells
- Cellular growth kinetics distinguish a cyclophilin inhibitor from an Hsp90 inhibitor as a selective inhibitor of hepatitis C virus
- Hsp90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells
- The Hsp90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
- Anti‐tumor activity of the Hsp90 inhibitor SNX‐2112 in pediatric cancer cell lines
- Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71
- Hsp90 inhibitor SNX5422/2112 targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell …
- IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class
- Hsp90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer
- A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a …
- Hsp90 inhibitor antagonizing MIF: the specifics of pleiotropic cancer drug candidates
- A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer’s mouse model via an HSF1-mediated …
- Elucidation of the Hsp90 C-terminal inhibitor binding site
- Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: A plausible therapeutic approach in Alzheimer’s disease
- … 1-[4-(2-{6-amino-8-[(6-bromo-
1, 3-benzodioxol-5-yl) sulfanyl]-9 H-purin-9-yl} ethyl) piperidin-1-yl]-2- hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor - The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent …
- A Novel Hsp90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer
- Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models
- 17-AAG, a Hsp90 inhibitor, attenuates the hypoxia-induced expression of SDF-1α and ILK in mouse RPE cells
- The Hsp90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal …
- A phase I dose escalation study of AUY922, a novel Hsp90 inhibitor, in patients with advanced solid malignancies
- Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
- An Hsp90 inhibitor, geldanamycin, as a brassinosteroid antagonist: evidence from salt-exposed roots of Vigna radiata
- Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal‐catalyzed oxidation
- … profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-
demethoxygeldanamycin, an inhibitor of the Hsp90 … - Radiosynthesis of the iodine‐124 labeled Hsp90 inhibitor PU‐H71
- Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials
- Combination therapy of NSCLC using Hsp90 inhibitor and doxorubicin carrying functional nanoceria
- MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells
- Oral administration of an Hsp90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice
- Radester, a novel inhibitor of the Hsp90 protein folding machinery
- The combination of Hsp90 inhibitor 17 AAG and heavy‐ion irradiation provides effective tumor control in human lung cancer cells
- The novel, orally bioavailable Hsp90 inhibitor NVP‐HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan …
- Anti-tumor activity of a novel, water soluble Hsp90 inhibitor IPI-504 in multiple myeloma
- Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib
- Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation
- Development of synthetic routes to macrocyclic compounds based on the Hsp90 inhibitor radicicol
- Inhibition of RPE cell sterile inflammatory responses and endotoxin-induced uveitis by a cell-impermeable Hsp90 inhibitor
- Antiproliferative effect of the Hsp90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer
- A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report.
- Discovery of a novel fluorescent Hsp90 inhibitor and its anti-lung cancer effect
- Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents
- 17-DMAG, an Hsp90 inhibitor, ameliorates multiple organ dysfunction syndrome via induction of HSP70 in endotoxemic rats
- A phase II study of Hsp90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase …
- Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network
- Elevated expression of Hsp90 and the antitumor effect of an Hsp90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic …
- Effects of Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice … - Preclinical pharmacokinetic analysis of SNX-2112, a novel Hsp90 inhibitor, in rats
- Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells
- The Hsp90 inhibitor 17-(allylamino)-17-
demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck … - First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (Hsp90) inhibitor AT13387 in refractory solid tumors.
- A novel small molecule Hsp90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo
- … protozoan infections biochemical characterization of Hsp90 from Plasmodium falciparum and trypanosoma evansi and evaluation of its inhibitor as a candidate drug
- p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin - Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model
- Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells
- Transformation of the non-selective aminocyclohexanol-based Hsp90 inhibitor into a Grp94-seletive scaffold
- The Hsp90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development
- Sti1 is a non-competitive inhibitor of the Hsp90 Atpase binding prevents the N-terminal dimerization reaction during the Atpase cycle
- Initial testing (Stage 1) of AT13387, an Hsp90 inhibitor, by the pediatric preclinical testing program
- Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor
- Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation
- Preclinical activity of the Hsp90 inhibitor, ganetespib, in ALK-and ROS1-driven cancers.
- Process development and scale-up of an Hsp90 inhibitor
- … )-[5-(4-methylpiperazin-1-
ylmethyl)-1, 3-dihydroisoindol-2-yl] methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug … - Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR …
- Inhibition of constitutive and cxc-chemokine-induced NF-κB activity potentiates ansamycin-based Hsp90-inhibitor cytotoxicity in castrate-resistant prostate …
- Combined Hsp90 and kinase inhibitor therapy: insights from the cancer genome Atlas
- Inhibition of thymidine phosphorylase expression by using an Hsp90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells
- Dose-escalation study of a second-generation non-ansamycin Hsp90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic …
- Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art
- Divergent synthesis of a pochonin library targeting Hsp90 and in vivo efficacy of an identified inhibitor
- The Hsp90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine
- Phase IB/II study of the Hsp90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer.
- Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development
- KU675, a concomitant heat-shock protein inhibitor of Hsp90 and Hsc70 that manifests isoform selectivity for Hsp90α in prostate cancer cells
- Low dose Hsp90 inhibitor 17AAG protects neural progenitor cells from ischemia induced death
- Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients …
- A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung …
- The Hsp90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer
- TAS-116, a novel Hsp90 inhibitor, selectively enhances radiosensitivity of human cancer cells to X-rays and carbon ion radiation
- The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a …
- Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 …
- First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q
- The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia …
- A novel Hsp90 inhibitor activates compensatory heat shock protein responses and autophagy and alleviates mutant A53T α-synuclein toxicity
- A phase I trial of the Hsp90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours
- A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel
- … -stabilized mesoporous carbon nanospheres as versatile carriers for systemic delivery of amphiphobic SNX-2112 (a Hsp90 inhibitor) with enhanced antitumor effect
- Leishmania donovani P23 protects parasites against Hsp90 inhibitor-mediated growth arrest
- Effect of Hsp90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation
- A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors
- Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors
- Antiproliferative effect of Hsp90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways
- Effect of the Hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions
- Expression of the protein chaperone, clusterin, in spinal cord cells constitutively and following cellular stress, and upregulation by treatment with Hsp90 inhibitor
- Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse …
- Preclinical activity of the novel orally bioavailable Hsp90 inhibitor NVP-HSP990 against multiple myeloma cells
- 5′‐N‐ethylcarboxamidoadenosine is not a paralog‐specific Hsp90 inhibitor
- A novel Hsp90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor …
- Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK‐independent cell cycle arrest
- Phase 1B/2 study of the Hsp90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab …
- In silico design of small peptide-based Hsp90 inhibitor: a novel anticancer agent
- Determination of SNX-2112, a selective Hsp90 inhibitor, in plasma samples by high-performance liquid chromatography and its application to pharmacokinetics in rats
- Efficacy of onalespib, a long-acting second-generation Hsp90 inhibitor, as a single agent and in combination with temozolomide against malignant gliomas
- … of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 inhibitor
- Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-
demethoxygeldanamycin - The Hsp90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model
- NAD (P) H: Quinone oxidoreductase-1 expression sensitizes malignant melanoma cells to the Hsp90 inhibitor 17-AAG
- Experience with Hsp90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma
- Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells
- Novel Hsp90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma
- Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells
- Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90
- Hsp90 inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells
- Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design
- Mitochondrial targeted Hsp90 inhibitor Gamitrinib-TPP (G-TPP) induces PINK1/Parkin-dependent mitophagy
- STA-8666, a novel Hsp90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma
- BIIB021, a novel Hsp90 inhibitor, sensitizes esophageal squamous cell carcinoma to radiation
- Efficient synthesis of Hsp90 inhibitor dimers as potential antitumor agents
- Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo
- Selective KIT inhibitor KI-328 and Hsp90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia
- 17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells
- The complementation of yeast with human or Plasmodium falciparum Hsp90 confers differential inhibitor sensitivities
- Hsp90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio
- Convergent synthesis and discovery of a natural product-inspired paralog-selective Hsp90 inhibitor
- Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program
- Dual PI3K-and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: the role of …
- Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein
- Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the Hsp90 inhibitor …
- Preclinical study of AUY922, a novel Hsp90 inhibitor, in the treatment of esophageal adenocarcinoma
- Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the Hsp90 inhibitor AUY922
- Hsp90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2
- Small molecule inhibitor screening identifified Hsp90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer
- The Hsp90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma
- Efficacy of an Hsp90 inhibitor, ganetespib, in preclinical thyroid cancer models
- The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation
- Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti‐inflammatory effects and interacts with glucocorticoid receptor in …
- Role of the novel Hsp90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy
- Anticancer effects of the Hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells
- BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF‑κB pathway …
- The decline of porcine sperm motility by geldanamycin, a specific inhibitor of heat-shock protein 90 (Hsp90)
- The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non …
- Assessment of the heat shock protein 90 (Hsp90) inhibitor IPI504 alone or in combination with the tyrosine kinase inhibitor (TKI) imatinib in mice carrying xenografts of …
- Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90
- SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG
- The Hsp90 inhibitor ganetespib alleviates disease progression and augments intermittent cyclophosphamide therapy in the MRL/lpr mouse model of …
- Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery
- VEGF downregulation by Hsp90 inhibitor NVP-AUY922 visualized with 89Zr-bevacizumab PET in triple negative breast cancer (TNBC)
- In vivo synergism between PARP-inhibitor olaparib and Hsp90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts.
- Acquired resistance to Hsp90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells
- … anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with …
- MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients.
- Targeted delivery of chemotherapy using Hsp90 inhibitor drug conjugates is highly active against pancreatic cancer models
- The mechanisms of apoptosis in HL-60 cells induced by Hsp90 inhibitor novobiocin
- Hsp90 inhibitor SY‑016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian cancer cells
- P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats
- The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human …
- Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α
- P-glycoprotein-evading anti-tumor activity of a novel tubulin and Hsp90 dual inhibitor in a non-small-cell lung cancer model
- … protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor …
- Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells by promoting activation of apoptosis-related proteins
- Discovery and pre-clinical profile of SNX-5422: an orally active Hsp90 inhibitor in phase 1 trials for solid and hematological tumors
- Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway
- Hsp90 inhibitor 17-DMAG exerts anticancer effects against gastric cancer cells principally by altering oxidant-antioxidant balance
- Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant …
- FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells
- Geldanamycin, an inhibitor of Hsp90, potentiates cytochrome P4502E1-mediated toxicity in HepG2 cells
- The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic …
- A phase II study of the Hsp90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
- The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes
- Dynamic proteomics reveals bimodal protein dynamics of cancer cells in response to Hsp90 inhibitor
- Geldanamycin, a potent and specific inhibitor of Hsp90, inhibits gene expression and replication of human cytomegalovirus
- A phase I study of Debio 0932, an oral Hsp90 inhibitor, in patients with solid tumors.
- Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells
- BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models
- The Hsp90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells
- The Hsp90 inhibitor 17-AAG represses calcium-induced cytokeratin 1 and 10 expression in HaCaT keratinocytes
- PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy
- HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor—PU-H71 (NSC 750424)
- Proliferation and apoptosis of leukemia cell line K562 treated with Hsp90 inhibitor 17-DMAG
- Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line …
- Abstract# 4679: The novel Hsp90 inhibitor STA-9090 has potent anticancer activity in in vitro and in vivo models of lung cancer
- A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma
- The novel Hsp90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE
- A phase I trial of the heat shock protein 90 (Hsp90) inhibitor 17-dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG, alvespimycin) administered … - The Hsp90 and DNA topoisomerase VI inhibitor radicicol also inhibits human type II DNA topoisomerase
- Phase l study assessing a two-consecutive-day (QD× 2) dosing schedule of the Hsp90 inhibitor, AT13387, in patients with advanced solid tumors
- Geldanamycin, an inhibitor of Hsp90 increases cytochrome P450 2E1 mediated toxicity in HepG2 cells through sustained activation of the p38MAPK pathway
- A phase I trial of the heat shock protein 90 (Hsp90) inhibitor alvespimycin (17-dimethylaminoethylamino-
17-demethoxygeldanamycin 17-DMAG) administered weekly … - Alternate Synthesis of Hsp90 Inhibitor AT13387
- A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
- Structural and computational biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-based inhibitor design
- A facile and efficient synthesis of d6‐labeled PU‐H71, a purine‐scaffold Hsp90 inhibitor
- Discovery of 2′, 4′-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC)
- Geldanamycin, an inhibitor of Hsp90, blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains
- NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases
- Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis
- Significance of long term pharmacodynamic actions of the Hsp90 inhibitor AT13387
- ATP acyl phosphate reactivity reveals native conformations of Hsp90 paralogs and inhibitor target engagement
- Activity of the proprietary Hsp90 inhibitor IPI-493 in models of colorectal cancer correlates with RAS pathway activation
- IPI-504, a novel orally administered Hsp90 inhibitor, demonstrates anti-tumor effects in EGFR mutant, kinase inhibitor resistant NSCLC
- Anti-tumor selectivity of a novel Tubulin and Hsp90 dual-targeting inhibitor in non-small cell lung cancer models
- Antiangiogenic activity of the Hsp90 inhibitor ganetespib in pancreatic cancer models
- NVP-AUY922, a novel Hsp90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo
- Hsp90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells
- Effects of Hsp90 inhibitor 17-AAG on cell cycle and apoptosis of human gastric cancer cell lines SGC-7901
- In vitro and in vivo antitumor activity of the next generation Hsp90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models.
- The Hsp90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells
- Radioiodination, biodistribution and PET imaging studies of Hsp90 inhibitor [124I]-PU-H71
- Comparative in vitro and in vivo metabolism of MPC-3100, an oral Hsp90 inhibitor, in rat, dog, monkey and human
- A combination of histone deacetylase inhibitor LBH589 and the Hsp90 inhibitor 17-AAG is highly active against human CML-BC and AML cells with constitutively …
- Preparation of the three C1-C7, C8-C15, and C16-N22 fragments of the Hsp90 inhibitor herbimycin A
- A phase I dose-escalation study of the Hsp90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR …
- RETRACTED ARTICLE: Potent antitumor activity of Hsp90 inhibitor AUY922 in adrenocortical carcinoma
- Hsp90 inhibitor AT-533 blocks HSV-1 nuclear egress and assembly
- Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening
- Combination of the mTOR inhibitor Rapamycin and Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin (17AAG) inhibits proliferation and induces apoptosis … - Hsp90 inhibitor reduces porcine circovirus 2 replication in the porcine monocytic line 3D4/31
- CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells
- Hsp90 inhibitor sensitizes TRAIL-mediated apoptosis via chop-dependent DR5 upregulation in colon cancer cells
- Inhibitor binding to Hsp90: a review of thermodynamic, kinetic, enzymatic, and cellular assays
- Comparison of long-term pharmacodynamic actions of the synthetic small molecule Hsp90 inhibitor AT13387 in multiple xenograft models
- Results of two phase 1 dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422
- Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)
- Image-guided photo-therapeutic nanoporphyrin synergized Hsp90 inhibitor in patient-derived xenograft bladder cancer model
- Targeting Hsp90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma
- Hsp90 inhibitor STA-9090 potently suppresses secondary KIT kinase-domain mutations responsible for gastrointestinal stromal tumor (GIST) progression …
- Pharmaceutical development of IPI‐504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer
- Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
- Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation
- BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1
- In vitro effect of AZD1208 (Pim Kinase Inhibitor) and 17-AAG (Hsp90 Inhibitor) combination in CLL.
- Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced …
- … by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor …
- Fragment-based drug discovery of the synthetic small molecule Hsp90 inhibitor AT13387
- IDH1057, A novel, synthetic, small molecule inhibitor of heat shock protein 90 (Hsp90)
- … Protein 90 (Hsp90) Chaperone Function in Patients with Metastatic GIST: Preliminary Results of a Phase I Trial of IPI-504, a Water-Soluble Hsp90 Inhibitor
- FS23 binds to the N-terminal domain of human Hsp90: a novel small inhibitor for Hsp90
- Ganetespib, an Hsp90 inhibitor, kills Epstein–Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood
- Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer
- Wee1-Hsp90 inhibitor combination treatment: molecular therapy with potentially broad applicability
- Hsp90 inhibitor CH5164840 induces micronuclei in TK6 cells via an aneugenic mechanism
- Dendritic hexadecapeptide as a cathepsin B degradable carrier for delivery of Hsp90 inhibitor
- The Hsp90 inhibitor, AT13387, displays single agent activity in erlotinib-sensitive and-resistant models of EGFR activated NSCLC
- Pan-HDAC inhibitor LBH589 depletes EZH2 and DNMT1 by inhibiting chaperone association of Hsp90 with EZH2 and DNMT1.
- Clinical efficiency and safety of Hsp90 inhibitor Novobiocin in avian tibial dyschondroplasia
- 17AEP-GA, an Hsp90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion
- The Hsp90 inhibitor 17-DMAG decreases infection of porcine circovirus type 2 in mice
- DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction
- Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations
- Effect of anacardic acid, a Hsp90 inhibitor, on proliferation, invasion and migration of breast cancer MDA-MB-231 cells
- Abstract A96: Phase 1 study of Hsp90 inhibitor MPC-3100 in subjects with refractory or recurrent cancer.
- Results from phase II trial of Hsp90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
- The novel Hsp90 inhibitor NVP-AUY922 shows synergistic anti-leukemic activity with cytarabine in vivo
- Synergistic interactions of the Hsp90 inhibitor 17AAG and the PI3K inhibitor LY294002 in non-small cell lung cancer (NSCLC) cell lines involve disruption of Akt and c …
- Abstract# 1857: The novel Hsp90 inhibitor, PU-H71, synergizes with cisplatin and blocks invasion and migration of ovarian cell lines.
- Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2‐amino‐7‐[4‐fluoro‐2‐(3‐
pyridyl) phenyl]‐4‐methyl‐7, 8‐dihydro … - C05. THE NEXT GENERATION Hsp90 INHIBITOR STA-9090, CURRENTLY IN PHASE 2 TRIALS, DISPLAYS POTENT IN VITRO AND IN VIVO ACTIVITY
- Phase I study of the Hsp90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.
- C-terminal Hsp90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition
- Abstract B98: AUY922, a novel Hsp90 inhibitor: Final results of a phase I dose escalation study in Japanese patients with advanced solid malignancies.
- Evaluation of the pharmacokinetics and efficacy of a novel pro-drug of the Hsp90 inhibitor, MPC-3100, designed with improved solubility
- [2+ 2+ 2] Cyclotrimerization with Propargyl Halides as Copartners: Formal Total Synthesis of the Antitumor Hsp90 Inhibitor AT13387
- Consecutive day Hsp90 inhibitor administration improves efficacy in murine models of KIT-driven malignancies and canine mast cell tumors
- Study on a Screening Model for Inhibitor of Hsp90 ATPase Activity [J]
- Addition of Hsp90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC; results of a randomized Phase 2 study
- … study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble Hsp90 inhibitor, 17-AAG, in …
- In vitro Cytotoxic Activities of the Oral Platinum (IV) Prodrug Oxoplatin and Hsp90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
- Proteasome inhibitor-induced cleavage of Hsp90 is mediated by ROS generation and caspase 10-activation in human leukemic cells
- Hsp90 Inhibitor Can Inhibit UV Carcinogenesis
- A novel, orally active, small molecule Hsp90 inhibitor.
- … of two novel Hsp90 proteins in Babesia orientalis: molecular characterization, and computational analyses of their structure, function, antigenicity and inhibitor …
- The Hsp90 inhibitor, 17-Allylamino-17-
Demethoxygeldanamycin (17AAG) abrogates the G2/M DNA damage checkpoint and induces apoptosis selectively in p53 … - Design of novel Geldanamycin analogue Hsp90 alpha-inhibitor in silico for breast cancer therapy
- CNF2024-The first clinical stage synthetic oral Hsp90 inhibitor
- … into whether the rapamycin inhibition of heat shock transcription factor (Hsf1) can prevent the Hsf1 activation that results from treatment with an Hsp90 inhibitor
- Discovery of the Serenex Hsp90 Inhibitor, SNX5422
- The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox
- The Hsp90 inhibitor, radicicol, attenuates bacterial lipopolysaccharide-induced endothelial permeability.
- Immunotherapeutic targeting of Hsp90 client proteins in BRAF-inhibitor resistant melanoma
- Discovery of licochalcone a as a natural product inhibitor of Hsp90 and its effect on gefitinib resistance in non-small cell lung cancer (NSCLC)
- Radicicol, a Hsp90 inhibitor, inhibits intestinal inflammation and leakage in abdominal sepsis
- Inhibitor-κB kinase attenuates Hsp90-dependent endothelial nitric oxide synthase function in vascular endothelial cells
- Effect of Hsp90 inhibitor novobiocin on STI571 resistant K562/G01 cells
- Antiviral evaluation of an Hsp90 inhibitor, gedunin, against dengue virus
- Metabolism and excretion of 6-chloro-9-(4-methoxy-3, 5-dimethylpyridin-2-ylmethyl)-
9H-purin-2-ylamine, an Hsp90 inhibitor, in rats and dogs and assessment of its … - Inhibition of thyroid cancer proliferation in vitro by a novel small molecule Hsp90 inhibitor.
- Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor
- Favorable interactions between fenretinide and the Hsp90 inhibitor 17AAG in neuroblastoma
- Hsp90 inhibitor is a good candidate for effective combination therapy with carbon ions
- Polymer mediated transport of the Hsp90 inhibitor LB76, a polar cyclic peptide, produces an Hsp90 cellular phenotype
- A purine scaffold Hsp90 inhibitor has antitumor activity in KSHV-associated malignancies by suppressing vFLIP
- 17-DMAG, an Hsp90 inhibitor, ameliorates ovariectomy-induced obesity in rats
- Expression of Hsp90 in a panel of human tumor explants and its relation to response to treatment with the Hsp90 inhibitor 17-AAG.
- Hsp90 Inhibitor Geldanamycin as a Radiation Response Modificator in Human Blood Cells
- Preclinical safety profile of tanespimycin (KOS-953)-a heat shock protein 90 (Hsp90) inhibitor
- Discovery of an L-alanine ester prodrug of the Hsp90 inhibitor, MPC-3100
- BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies
- Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG
- Potent anticancer actions of the Hsp90 inhibitor STA-9090 in wild-type EGFR models of lung cancer
- The Hsp90 inhibitor, onalespib (AT13387), delays the emergence of resistance to erlotinib in an EGFR-driven xenograft model
- NVP-AUY922, a novel diarylisoxazole resorcinol Hsp90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts
- Hsp90 inhibitor STA-9090 induces HIF-1α degradation in the hypoxic regions of solid tumors
- … POSTER Modulation of the Hsp90 co-chaperone AHA1 affects client protein activity and increases cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17 …
- Combination of the Hsp90 inhibitor, 17AAG, with taxol in human ovarian tumour cell lines
- Effects of cotreatment or sequence treatment with Hsp90 C-terminal inhibitor NB and Hsp90 N-terminal inhibitor GA on leukemia cells
- Hsp90 inhibitor induces KG-1a cell differentiation and apoptosis via Akt/NF-κB signaling
- Delivery of Hsp90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload
- Acquired resistance to Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin (17-AAG) in adult and pediatric glioblastoma cell lines - Simultaneously targeting hypoxic cancer cells by Hsp90 inhibitor and glycolysis inhibitor in pancreatic cancer therapy
- ATPS-05CHARACTERIZATION OF THE ACTIVITY OF AT13387, A NOVEL SECOND GENERATION Hsp90 INHIBITOR AGAINST GLIOMAS
- Blood-brain-barrier–permeable Hsp90 inhibitor reduces soluble tau burden in a mouse model of Alzheimer’s disease
- Abstract B199: In vitro and in vivo efficacy of the novel Hsp90 inhibitor STA‐9090 and its synergy with paclitaxel
- The effect of EC78, a novel Hsp90 inhibitor alone and in combination with radiation in head and neck squamous cell carcinoma
- Progesterone Receptor Chaperone Complex–Based High-Throughput Screening Assay: Identification of Capsaicin as an Inhibitor of the Hsp90 Machine
- Hsp90 inhibitor NMS-E973 exerts the anticancer effect against glioblastoma via induction of PUMA-mediated apoptosis
- Model system identifies kinetic driver of Hsp90 inhibitor activity against African trypanosomes and Plasmodium falciparum
- IPI-504, a novel Hsp90 inhibitor is effective in EGFR T790M and non-T790M gefitinib-resistant lung cancer cell lines.
- Ribosome Profiling Reveals Hsp90 Inhibitor Effects on Stage-Specific Protein Synthesis in Leishmania donovani
- Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922
- Phase I study of vemurafenib and heat shock protein 90 (Hsp90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.
- Hsp90 inhibitor induces cell cycle arrest and apoptosis of early embryos and primary cells in pigs
- Hsp90 inhibitor geldanamycin reverts IL-13–and IL-17–induced airway goblet cell metaplasia
- Hsp90 inhibitor STA-9090 enhances the activity of standard of care therapies in erlotinib-sensitive and-resistant NSCLC models
- Abrogation of hsp70 induction: A strategy to enhance the antileukemia effects of Hsp90 inhibitor 17-allylamino-demethoxy geldanamycin (17-AAG)
- Hsp90 Inhibitor 17-AAG Inhibits Multiple Myeloma Cell Proliferation by Down-regulating Wnt/β-Catenin Signaling Pathway
- Hsp90 inhibitor 17-DMAG effectively alleviated the progress of thoracic aortic dissection by suppressing smooth muscle cell phenotypic switch
- TM-03THE Hsp90 INHIBITOR GANETESPIB IS AN EFFECTIVE THERAPY FOR GLIOBLASTOMA THAT BLOCKS EGFR-DRIVEN TUMOR GROWTH
- Inhibition of Hsp90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells
- Preclinical testing demonstrates strong activity of STA-12-8666, an Hsp90 inhibitor-SN-38 conjugate, in small cell lung cancer (SCLC)
- OA 12.02 final results of a phase 2 study of the Hsp90 Inhibitor Luminespib (AUY922) in NSCLC patients harboring EGFR Exon 20 insertions
- A phase I study of the Hsp90 inhibitor AUY922 plus capecitabine for the treatment of patients with advanced solid tumors
- Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer
- Biological effects of the novel small molecule Hsp90 inhibitor SNX-2112 as a single agent and in combination with Erlotinib in non-small cell lung cancer models
- P2. 13-39 a phase Ib trial of the Hsp90 inhibitor AUY922 in combination with Pemetrexed in metastatic non-squamous, non-small cell lung cancer patients
- Mechanism of Inhibition of Hsp90 Dimerization by Gyrase B Inhibitor Coumermycin A1 (C–A1) Revealed by Molecular Dynamics Simulations and Thermodynamic …
- A novel, selective, orally active, potent small molecule inhibitor of Hsp90
- 2‐phenylethynesulphonamide (PFT‐μ) enhances the anticancer effect of the novel Hsp90 inhibitor NVP‐AUY922 in melanoma, by reducing GSH levels
- The novel Hsp90 inhibitor IPI-504 synergizes with bortezomib in mantle cell lymphoma cells by targeting both NF-kappaB signaling and unfolded protein response …
- Abstract A110: A phase 1 study of PF‐04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with …
- A novel Hsp90 inhibitor, 17-DMAG, induces Tax down-regulation and its oral administration to ATL-model mice intervenes against the infiltration property of the ATL …
- 17-AAG (KOS-953), an inhibitor of Hsp90 function, significantly enhances the cytotoxicity of anticancer drugs: An effective approach for combination therapy
- Part I of GANNET53: A European multicenter Phase I/II trial of the Hsp90 inhibitor Ganetespib combined with weekly Paclitaxel in women with high-grade, platinum …
- Triptolide, a Hsp90 middle domain inhibitor, induces apoptosis in triple manner
- Molecular dynamics simulations of Hsp90 with an eye to inhibitor design
- 1479PDPhase II study of TAS-116, an oral inhibitor of heat shock protein 90 (Hsp90), in metastatic or unresectable gastrointestinal stromal tumor refractory to …
- … (PD) study of 17-dimethylaminoethylamino-17-
demethoxygeldanamycin,(17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (Hsp90), in patients with … - Chetomin as a Potent Hsp90 Inhibitor
- Thermodynamics of Natural and Synthetic Inhibitor Binding to Human Hsp90
- Development of Polymeric-Drug Conjugates for Delivering the Hsp90 Inhibitor SNX5422
- Hsp90 Inhibitor Treatment for Cushing Syndrome and Other Diseases
- Analysis of Genes Regulated by Hsp90 Inhibitor Geldanamycin in Neurons
- Repositioning Irsogladine to Hsp90 Inhibitor
- A novel inhibitor to disrupt Hsp90-Cdc37 interaction against pancreatic cancer
- Identification of Hsp90 inhibitor sensitizers through pooled RNA interference screen
- Abstract B19: The Hsp90 inhibitor, AT13387, is effective against multiple mechanisms of kinase inhibitor resistance
- Abstract B90: Hsp90 inhibitor NVP-AUY922 sensitizes intrinsic MEK inhibitor Trametinib-resistant NSCLC cells harboring KRAS mutation
- Preclinical efficacy of PF-04942847, a novel Hsp90 inhibitor, in osteosarcoma
- Hsp90 Inhibitor Enhances the Pgd2-stimulated Hsp27 Induction in Osteoblasts
- Novel Hsp90 inhibitor, STA-9090, for combination with radiotherapy
- A new Hsp90 inhibitor as therapeutic agent for bladder cancer.
- Hypoxic Radiosensitization By DMAG, an Hsp90 Inhibitor
- A novel small molecule inhibitor of heat shock protein 90 (Hsp90)
- Preclinical evaluation of WXFL1024H251, a potent second-generation Hsp90 inhibitor
- Synthesis of the seco‐Limonoid BCD Ring System Identifies a Hsp90 Chaperon Machinery (p23) Inhibitor
- Combinatorial targeting of oncogenesis via a novel rationally designed Hsp90 inhibitor
- Development of the high-throughput screening fluorescence polarization assay for Hsp90 inhibitor
- Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer
- The Hsp90 inhibitor Ganetespib: A Potential Effective
- Hsp90 inhibitor, 17-DMAG, enhances radiosensitivity of human cancer cells
- Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain
- Abstract B1: Targeting KRAS mutant NSCLC with the Hsp90 inhibitor ganetespib
- FS-108, an Hsp90 inhibitor, impairs survival and motility of oncogene addicted cancer cells
- Hsp90 Inhibitor Strengthens Atp-stimulated Interleukin-6 Synthesis in Osteoblasts
- Hsp90 inhibitor drug conjugates (HDCs): Proof of concept in preclinical studies
- The design and synthesis of a novel orally available Hsp90 inhibitor CH5164840
- Phase 1 study of onalespib, Hsp90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors.
- … Inhibitor Enhances Hsp90 Inhibitor-mediated Abrogation of Hsp90 Chaperone Function and Potentiates the Cytotoxicity of Hsp90 Inhibitor in Chemo-resistant …
- Hsp90 inhibitor has a possibility to overcome imatinib resistance in gastrointestinal stromal tumors
- Effectiveness of the combined treatment with Hsp90 inhibitor and heavy ion irradiation
- The novel Hsp90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma
- Abstract A212: A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor‐induced apoptosis in HCT116 colon carcinoma cells
- Hsp90 and histone deactylase inhibitor have synergistic activity against synovial sarcoma.
- Hsp90 inhibitor (NVP-AUY922) enhances anti-cancer effect of Bcl-2 inhibitor (ABT-737) in small cell lung cancer
- Abstract# 4690: Preclinical characterization of the Hsp90 inhibitor XL888 in melanoma models
- Moleculary Targeted Nanomedicine: Role of Hsp90 Inhibitor and Sophorolipids
- Discovery of a novel small inhibitor RJ19 targeting to human Hsp90
- Molecular profile and anti-myeloma activity of the novel Hsp90 inhibitor NVP-AUY922
- Inhibition of signal transduction by the Hsp90 inhibitor sensitizes human tumor cells to radiation
- Chemical approaches to development of mitochondrial-targeted Hsp90 inhibitor in anti-cancer therapeutics: Mechanism and structure change of mitochondrial Hsp90
- Essential oil from Cymbopogon flexuosus as the potential inhibitor for HSP90
- Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation
- Preclinical antitumor activity of SST0116CL1, a novel heat shock protein 90 (Hsp90) inhibitor
- Radiosensitization induced by 17DMAG: An orally bioavailable inhibitor of HSP90
- AT13387, an Hsp90 inhibitor, is effective in both vemurafenib-sensitive and-resistant melanoma models
- Treatment of Arabidopsis thaliana seeds with an Hsp90 inhibitor increases plant resistance
- Treatment of advanced bronchoalveolar carcinoma with the Hsp90 inhibitor STA-9090.
- Abstract B100: Preclinical evaluation of a novel Hsp90 inhibitor HSP990 in glioblastoma multiforme.
- The investigation of AT7519 (CDK inhibitor) and AT13387 (Hsp90 inhibitor) as novel therapies for the treatment of pancreatic ductal adenocarcinoma
- Identification of vibsanin A analog as a novel Hsp90 inhibitor
- Abstract# 4678: Preclinical anti-myeloma activity of the novel Hsp90 ATPase inhibitor NVP-BEP800
- Overcoming acquired resistance to BRAF inhibitors in melanoma with the Hsp90 inhibitor ganetespib
- Identification of the ellagitannin geraniin as a novel Hsp90 inhibitor
- Effect of Hsp90 inhibitor ganetespib on stemness in small cell lung cancer
- Chemotherapeutic potential of Hsp90 and biological evaluation of a novel Hsp90 inhibitor
- Gene Expression Profile of Apoptosis in Leukemia Cells Induced by Hsp90 Selective inhibitor 17-AAG
- NVP-AUY922: A novel small molecule Hsp90 inhibitor with potent in vivo antitumor efficacy
- Hsp90 inhibitor AUY922 abrogates mTOR inhibitor AZD8055-induced up-regulation of HER2/HER3 and potentiates antiproliferative activity in human breast cancer …
- The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor
- The Hsp90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and crizotinib-resistant MET-driven renal tumor models
- The Hsp90 inhibitor ganetespib is a potent chemosensitizer in preclinical colorectal cancer models
- Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity
- Results of toxicology studies with MPC-3100, an oral Hsp90 inhibitor.
- Identification and validation of serum biomarkers for clinical assessment of Hsp90 inhibitor therapy
- AT-533, a Hsp90 inhibitor, attenuates HSV-1-induced inflammation
- Hsp90 Inhibitor, 17-AAG, Affects Meiotic Maturation and Preimplantation Embryos Development in Pigs.
- Novel in vivo pan-Hsp90 family protein inhibitor, Panvotinib-401, showed potent anticancer activities without HSF1 activation
- The novel Hsp90 inhibitor STA-12-1474 exhibits biologic activity against canine osteosarcoma cell lines
- Abstract B88: Mechanisms of resistance to the Hsp90 inhibitor ganetespib in triple negative breast cancer
- Proteasome inhibitor‐induced protein aggregation is regulated via HSP90, HDACs and microtubulus stability in ARPE‐19 cells
- Hsp90-inhibitor drug conjugates (HDC): Novel tumor-selective drug delivery platform with unprecedented anticancer activity
- NVP-AUY922/VER-52296: A novel 3, 4 diarylisoxazole Hsp90 chaperone inhibitor discovered via structure-based drug design
- Hsp90-inhibitor Ganetesbip potentiates radiosensitizing and chemosensitizing effects of hyperthermia
- Development of a noninvasive assay to determine drug concentration in tumor during Hsp90 inhibitor therapy
- (-)-Epigallocatechin-3-
gallate, Found in the Green Tea Extract, is a Novel Hsp90 Inhibitor - Molecular detection of Hsp90 inhibitor suppressing PCV2 replication in host cells
- Antitumor activity of MPC-3100, a synthetic, orally bioavailable Hsp90 inhibitor, in animal models
- The effects of Hsp90 inhibitor DMAG on the leukemia cell line HL-60
- The Hsp90 inhibitor 17-AAG improves chemoresistance of cisplatin-resistant esophageal squamous cell carcinoma cell lines
- Synthesis of isotope‐labeled Hsp90 inhibitor: [13CD3] and [14C]‐TAK‐459
- Hsp90 inhibitor, 17-allylaminogeldanamycin, inhibits cell growth of lung cancer cell lines associated with overexpression of Hsp90 on lung cancer tissues.
- The Hsp90 inhibitor ganetespib potentiates effect of ionizing radiation in human non-small cell lung cancer
- DEBIO0932, an Hsp90 inhibitor downregulates key signaling pathways and sensitizes glioma cells to temozolomide
- The Research and Analysis of Global Market about Hsp90 Inhibitor from Microbiology
- Hsp90 inhibitor 17-DMAG enhances EphA2+ tumor cell recognition by specific CD8+ T cells (40.27)
- Novel inhibitor of Hsp90-PU-H71 exhibits significant activity in Ewing sarcoma pre-clinical models.
- Synthesis of an 18F labeled pyrazole-based Hsp90 inhibitor for PET imaging of cancers
- 601 The Antimyeloma Activity of PU-H71, a Novel Purine Scaffold Hsp90 Inhibitor, is via Inhibition of Both HSP90A and HSP90B1
- The Hsp90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC
- Efficacy of the Hsp90 inhibitor NVP-AUY922 correlates with decreased vessel permeability and reduced interstitial fluid pressure
- Abstract# LB-86: Probing cancer-specific activating signaling pathways through a tumor-specific Hsp90 inhibitor
- Ganetespib, an Hsp90 Inhibitor, Sensitizes Colorectal Cancers to the Effects of Ionizing Radiation
- MPC-3100, a synthetic Hsp90 inhibitor, induces biomarker changes in vitro and in vivo
- ET-14. PRECLINICAL EVALUATION OF NXD30001, A NOVEL Hsp90 INHIBITOR, FOR EFFICACY IN GLIOMA
- Identification and development of NVP-HSP990, a potent and orally active Hsp90 inhibitor for cancer treatment
- Potent antitumor activity of the Hsp90 inhibitor SNX-2112 in type 1 papillary renal cell carcinoma
- The Hsp90 Inhibitor 17-AAG Prevents Aberrant Endocytosis Mediated By The Rhodopsin Retinitis Pigmentosa R135L Mutation
- Abstract LB-140: The Hsp90 inhibitor ganetespib overcomes EGFR-based intratumoral heterogeneity to block glioma proliferation
- Determining the Effect of Hsp90 Inhibitor Geldanamycin on Herpes Simplex Virus Type-1 Production in Infected Vero Cells
- Effect of the Hsp90 Inhibitor KW-2478 on HepG2 Cells.
- Abstract LB-187: Hsp90 inhibitor SNX-2112 enhances neoantigen presentation on the surface of tumor cells
- Signaling Profile and Anti-Tumor Activity of the Novel Hsp90 Inhibitor NVP-AUY922 in Multiple Myeloma.
- The Hsp90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells
- Preclinical evaluation of the novel, potent diarylisoxazole resorcinol Hsp90 inhibitor NVP-AUY922 in adult and pediatric glioblastomas
- Activity of PU-H71, a novel Hsp90 inhibitor, and bortezomib in Ewing sarcoma preclinical models.
- The Hsp90 Inhibitor, AUY-922 Reduces Pulmonary Fibrosis and Airway Dysfunction in Mice Exposed to HCl
- Abstract# 5632: NVP-BEP800: an orally bioavailable small molecule Hsp90 inhibitor with potent in vivo antitumor activity
- 52. A Novel Small Molecule Hsp90 Inhibitor With Antiproliferative Effects in Differentiated and Anaplastic Thyroid Cancers
- Targeting Hsp90 using EC154, a novel synthetic Hsp90 inhibitor, impairs multiple signaling pathways in human gastric and pancreatic cancer cells and reduces tumor …
- Preclinical evaluation of the Hsp90 inhibitor KW-2478 in combination with bortezomib as a treatment for multiple myeloma
- Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold Hsp90 inhibitor.
- Clinical and biological significances of heat shock protein 90 (Hsp90) in human nasopharyngeal carcinoma cells and anti-cancer effects of Hsp90 inhibitor
- Antitumor activity of MPC-3100, a synthetic Hsp90 inhibitor, in combination with erlotinib and sorafenib
- Biological Evaluation of Natural Product as a Potent Hsp90 Inhibitor.
- Design, synthesis, and biological evaluation of small molecule as Hsp90 inhibitor
- 26 BC265: A Nonquinone Ansamycin Hsp90 Inhibitor Developed Using Biosynthetic Medicinal Chemistry
- Experimental study on mouse bone marrow micronucleus of a novel Hsp90 inhibitor-SNX-2112
- Abstract B101: Safety, tolerability, and pharmacokinetics of IPI-493, an oral Hsp90 inhibitor, in patients with advanced cancers.
- Abstract A213: Potent anticancer activity in vitro and in vivo by NMS‐E973, a novel synthetic inhibitor of HSP90
- The Hsp90 inhibitor PU-H71 is a potent suppressor of metastasis in triple-negative breast cancer models
- Abstract A218: Pharmacokinetic (PK) and pharmacodynamic (PD) data for MPC‐3100, a fully synthetic Hsp90 inhibitor, in cancer patients
- BJ-B11, an Hsp90 Inhibitor, Constrains the Proliferation and Invasion of Breast Cancer Cells
- Antitumor activity of heat shock protein 90 (Hsp90) inhibitor AT13387 in head and neck squamous cell carcinoma
- Preclinical efficacy of the Hsp90 inhibitor SNX-5422 in targeting C481S mutant BTK and ibrutinib resistant CLL
- Hsp90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
- The Hsp90 Inhibitor Radicicol As A Bioinformatically-Derived Drug For M2 Macrophage Phenotype Inhibition
- Multimodal action of the Hsp90 inhibitor STA-9090 in treating cancer cells with activated JAK/STAT signaling
- A specific Hsp90 small molecular inhibitor demonstrates anti-tumor activity in melanoma cells through V600E B-Raf protein degradation
- Abstract# 1853: Cancer cells harboring MET gene amplification are sensitive to Hsp90 inhibitor 17-AAG
- STA-12-8666: a first-in-class Hsp90 inhibitor drug conjugate (HDC) designed to selectively deliver chemotherapy to tumors
- A Novel Hsp90 Inhibitor to Disrupt HSP90/p50CDC37 Complex for Pancreatic Cancer Therapy.
- Activity of the heat shock protein 90 (Hsp90) inhibitor, SNX-2112, in pediatric cancer cell lines.
- Abstract# 4682: BIIB021, a fully synthetic oral small molecule inhibitor of Hsp90, shows anti-tumor activity in multiple xenograft models.
- Activity of Hsp90-inhibitor drug conjugate (HDC) STA-12-8666 in preclinical models of pediatric sarcoma.
- The advances of the Hsp90 inhibitor NVP-AUY922: applied alone or in combination with anti-tumor treatment
- The Hsp90 inhibitor, 17-AAG, reduces pulmonary arterial calcineurin activity in monocrotaline-induced pulmonary arterial hypertension (PAH)
- Targeting Hsp90 using EC154, a novel synthetic Hsp90 inhibitor, impairs multiple oncogenic signaling pathways in human gastric and pancreatic cancer cells and …
- Pre-clinical and clinical evaluation of the heat shock protein 90 (Hsp90) inhibitor 17-allylamino, 17-demethoxygeldanamycin.
- Human cytochrome P450 and UDP-glucuronosyltransferase reaction phenotyping of MPC-3100, an oral Hsp90 inhibitor.
- Hsp90 Inhibitor-Based Strategies for Cancer Therapy: Advancing Toward Clinical Impact
- Protein–protein inhibitor designed de novo to target the MEEVD region on the C-terminus of Hsp90 and block co-chaperone activity
- Activity of IPI-504, a water-soluble Hsp90 inhibitor, combined with bortezomib in a human multiple myeloma xenograft model
- Abstract B105: Ganetespib, a unique resorcinolic Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile in preclinical models.
- Hsp90 inhibitor SY-016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian
- Topically applied Hsp90 inhibitor 17-(allylamino)-17-
demethoxygeldanamycin inhibits ultraviolet radiation-induced development of cutaneous squamous cell … - Hsp90 inhibitor induces nuclear translocation of HSF1 predominantly in hippocampal CA1 region
- Post-treatment with the heat shock protein 90 (Hsp90) inhibitor, AUY-922, reduces lung Hsp90 tyrosine (Y) phosphorylation and pulmonary inflammation in LPS …
- The Hsp90 Inhibitor, 17-AAG Prevents The Progression Of Monocrotaline-Induced Right Ventricular Hypertrophy And Pulmonary Arterial Hypertension
- Abstract B105: Hsp90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes
- Combined treatment wth Hsp90 inhibitor and TRAIL down-regulated NFκB activity through their effects on the death receptor complex.
- Proteomic analysis of Hsp90 inhibitor effects on human leukemia cells
- Abstract# 1922: Antitumor activity of CUDC-305, a novel oral Hsp90 inhibitor, in solid and hematological tumor xenograft models
- Synthesis and biological evaluation of geldanamycin–ferulic acid conjugate as a potent Hsp90 inhibitor
- Hsp90 inhibitor NVP-AUY922 exhibits the potent antiproliferative effect in gastrointestinal cancer cells with a lack of PTEN expression
- Hsp90 inhibitor DPB induces autophagy and more effectively apoptosis in A549 cells combined with autophagy inhibitors
- A Hsp90 inhibitor, AUY922, is effective to overcome the MET-and AXL-mediated resistance to EGFR-TKI in lung cancer
- Abstract# 5649: Pharmakokinetic/phamacodynamic relationship of the Hsp90 inhibitor NVP-AUY922 in human xenografts and patients in a clinical Phase I trial
- MEK-inhibitor PD184352 enhances the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922: the role of cell type and drug-irradiation schedule
- Discovery of a novel butein derivative as a promising Hsp90 inhibitor
- Cassette dosing in tumor bearing animals for the discovery of NVP-AUY922, a novel Hsp90 inhibitor.
- Antiproliferative effects and signaling profiles of the novel Hsp90 inhibitor NVP-AUY922 in non-small cell lung cancer
- Pharmacokinetics (PK) and toxicology of KOS-1022, an orally administered heat shock protein 90 (Hsp90) Inhibitor
- The novel Hsp90 inhibitor, PF-04929113, inhibits AR activity and osteoclastogenesis and delays castrate-resistant LNCaP prostate cancer tumor growth
- Effect of Hsp90 inhibitor NVP-AUY922 with radiation on lung adenocarcinoma cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors
- Evaluating the Hsp90 Inhibitor Ganetespib as a Radiosensitizing Agent in Breast Cancer Models In Vitro
- Modulation of AHA1: A novel therapeutic strategy to increase cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin (17-AAG) - Abstract B14: Hsp90-inhibitor drug conjugate STA-12-8666 demonstrates complete tumor regression in preclinical models of pediatric sarcoma
- Development and validation of a highly sensitive ELISA method for the quantitation of Hsp70-a tumor biomarker associated with Hsp90 inhibitor therapy
- Abstract# 3998: 89Zr-trastuzumab immunoPET visualizes HER2 downregulation induced by the Hsp90 inhibitor NVP-AUY922 in human tumor xenograft
- Role of NAD (P) H: quinone oxidoreductase 1 (NQO1) in the cytotoxicity of the Hsp90 inhibitor 17AAG in human pancreatic cancer cells
- Abstract B184: Hsp90 inhibitor STA‐9090 potently suppresses heterogeneous KIT kinase‐domain mutations responsible for gastrointestinal stromal tumor …
- Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment
- A research of apoptosis-inducing effects of APL cells NB4 by an Hsp90 inhibitor HDN-1
- Retraction: Novel Hsp90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig 2-Positive Glioma Tumor–Initiating Cells
- Abstract A217: The Hsp90 inhibitor AT13387 demonstrates potent antitumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor …
- Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation
- Zr-bevacizumab PET imaging of early anti-angiogenic tumor response to treatment with Hsp90 inhibitor NVP-AUY922
- Non-steroidal anti-inflammatory drugs sensitize CD44-overexpressing cancer cells to Hsp90 inhibitor through autophagy activation
- Abstract C130: The Hsp90 inhibitor ganetespib promotes the degradation of FGFR3 in bladder cancer models and induces regression in tumors harboring oncogenic …
- Hs-27, a Novel Hsp90 Inhibitor, Exhibits Diagnostic and Therapeutic Potential in Triple Negative Breast Cancer
- Abstract A214: A novobiocin analogue Hsp90 inhibitor induces apoptosis and has potent antitumor effects in head and neck squamous cell cancer in vivo
- The Hsp90 inhibitor FW-04-806 suppresses Bcr/Abl-mediated growth of leukemia cells by inhibiting proliferation and inducing apoptosis
- PO-440 Targeting of triple negative breast tumours using liposomes as drug delivery systems for sirna and Hsp90 inhibitor
- Abstract A215: Hsp90 inhibitor IPI‐504 demonstrates antitumor activity against a panel of neuroendocrine/carcinoid cell lines in vitro and in vivo
- Hsp90 inhibitor 17‐AAG prevents apoptosis of cardiomyocytes via miR‐93–dependent mitigation of endoplasmic reticulum stress
- Clinical Development of Gamitrinib, a Novel Mitochondrial-Targeted Small Molecule Hsp90 Inhibitor
- … protozoan infections: biochemical characterization of Hsp90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug
- Differing mechanisms of synergistic interaction of the Hsp90 inhibitor 17-AAG and TRAIL in resistant colon cancer cell lines
- Preclinical evidence of synergism between DNA damaging agents and the Hsp90 Inhibitor, 17-DMAG, in tumors with mutant p53
- Abstract# LB-7: Targeting triple-negative breast cancer via PU-H71, a purine-scaffold heat shock protein 90 (Hsp90) inhibitor
- C76 HEAT SHOCK PROTEIN: The Hsp90 Inhibitor Radicicol As A Bioinformatically-Derived Drug For M2 Macrophage Phenotype Inhibition
- Hsp90 inhibitor 17-allylamino-geldanamycin enhances sensitivity to double-strand DNA break-inducing agents (platinum and PARP inhibitors) in epithelial ovarian …
- Combining the Hsp90 inhibitor, AT13387, with vemurafenib delays the emergence of resistance in a preclinical model of BRAF V600E mutant melanoma.
- Mechanism of resistance to 17-DMAG, an Hsp90 inhibitor, in lung cancer cell lines with ALK rearrangement
- Identification of synergistic drug combinations with the oral Hsp90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancer
- Radiosensitization by post-irradiation treatment with an Hsp90 inhibitor, 17-DMAG, in the p53 mutant pancreatic cancer cell line, MiaPaca2
- Expedient Access to 2‐Benzazepines by Palladium‐Catalyzed C− H Activation: Identification of a Unique Hsp90 Inhibitor Scaffold
- Potent activity of the heat shock protein 90 (Hsp90) inhibitor, 17AAG in head and neck squamous cell carcinoma (HNSCC) lines
- Phase I evaluation of STA-1474, a pro-drug of the novel Hsp90 inhibitor STA-9090, in dogs with spontaneous cancer
- Blood-brain barrier permeable Hsp90 inhibitor reduces soluble tau burden and rescues tau-dependent phenotype in a mouse model of tau accumulation
- The effects of a novel Hsp90 inhibitor——SNX-2112 on hepatis metablic enzymes in rats
- Demonstrating preclinical efficacy of AUY922, a novel Hsp90 inhibitor, alone and in combination with standard chemotherapy or radiation in esophageal …
- Cover Picture: Discovery and Biological Activity of 6BrCaQ as an Inhibitor of the Hsp90 Protein Folding Machinery (ChemMedChem 5/2011)
- Preclinical investigation of the Hsp90 inhibitor, ganetespib, in combination with FDA-approved cytotoxic agents for their potential anti-tumor effects on human …
- 4-Amino-substituted 5-resorcinol-isoxazole derivatives, a novel class of Hsp90 inhibitor: Synthesis and evaluation of in vitro activity
- Abstract# 4712: The Hsp90 inhibitor IPI-504 inhibits proliferation and tumor growth of HER2 overexpressing breast cancer cells with acquired trastuzumab resistance
- Abstract C91: Pharmacodynamic analysis of the Hsp90 inhibitor STA‐9090 in a lung cancer xenograft model supports an infrequent dosing schedule in the clinic
- Targeting angiogenesis and tumor growth with the Hsp90 inhibitor NVP-AUY922 in a model of pancreatic cancer: impact on cMet, VEGFR2 and PDGFR signaling
- IPI-504, a selective Hsp90 inhibitor is biologically active and tolerated in combination with trastuzumab in preclinical models of HER2 positive tumor xenografts
- Enhancement by Hsp90 inhibitor of PGD2-stimulated HSP27 induction in osteoblasts: suppression of SAPK/JNK and p38 MAP kinase
- Hsp90 inhibitor SNX-2112 inhibits cell growth by regulating Bcl-2 family proteins and cyclin proteins in MCF-7 cells
- Identification of the circRNA-miRNA-mRNA regulatory network of Hsp90 inhibitor-induced cell death in colorectal cancer by integrated analysis
- Preclinical efficacy of STA-12-8666, an Hsp90 inhibitor-targeted SN-38 conjugate, in small cell lung cancer (SCLC).
- BAG3‐dependent expression of Mcl‐1 confers resistance of mutant KRAS colon cancer cells to the Hsp90 inhibitor AUY922
- First-in-human phase I study of an oral Hsp90 inhibitor, TAS-116, in patients with advanced solid tumors
- P03. 09 AUY922, A NOVEL Hsp90 INHIBITOR EFFECTIVE AGAINST ABC-DLBCL AND MALT LYMPHOMA CELLS HARBORING GENETIC ALTERATION …
- Abstract# 4686: The molecular and biological effects of KW\# 8722; 2478, a novel non-ansamycin Hsp90 inhibitor, on multiple myeloma cells having various IgH …
- C1-07: IPI-504, a novel Hsp90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines.
- First-in-human phase I study of an oral Hsp90 inhibitor, TAS-116, in advanced solid tumors.
- C-terminal Hsp90 inhibitor, L80, targets cancer stem cell (CSC)-like property and suppresses metastasis via JAK/STAT3 inactivation in triple-negative breast cancer
- Abstract# 5650: The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma by downregulation of the prosurvival ER chaperone BiP …
- Hsp90 inhibitor 17-AAG plays an important role in JAK3/STAT5 signaling pathways in HTLV-1 infection cell line HUT-102
- Evaluating the Therapeutic Effect of an Hsp90 Inhibitor in Mouse Models of Alzheimer’s Disease
- 5.26 Hsp90 Inhibitor Restores P53-Mutated MEC1 Chronic Lymphocytic Leukemia Cell Sensitivity to Fludarabine by Downregulating DNA Repair and Endoplasmic …
- Novel Hsp90 Inhibitor C086 Potently Inhibits Non-Small Cell Lung Cancer Cells As A Single Agent Or In Combination With Gefitinib
- Combination immunotherapy integrating Hsp90 inhibitor 17-DMAG reconditions the tumor microenvironment for improved T cell recruitment and anti-tumor efficacy …
- 1622P Heat shock protein 90 (Hsp90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor …
- Hsp90 inhibitor, NVP-AUY922, improves myelination in vitro and supports the maintenance of myelinated axons in neuropathic mice
- Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (Hsp90) inhibitor XL888 in advanced BRAFV600 mutant melanoma.
- ET-41. A NOVEL Hsp90 INHIBITOR, NVP-HSP990, TARGETS CELL CYCLE REGULATORS TO PRODUCE AN ANTI-GLIOMA EFFECT IN OLIG2-EXPRESSING …
- Abstract# 1855: The novel Hsp90 inhibitor NVP-AUY922 reduces insulin-like growth factor receptor type 1 expression and lowers migration rate in triple-negative …
- Hsp90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators
- … # 4687: OSU-HDAC42, a novel HDAC inhibitor, exhibits biologic activity against human and canine malignant mast cells through both histone dependent and Hsp90 …
- Erratum to: A novel small molecule Hsp90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo
- Abstract# 2937: A purine scaffold heat shock protein 90 (Hsp90) inhibitor destabilizes BCL6 and has specific anti-tumor activity in BCL6 dependent lymphomas in vitro …
- Abstract B80: Hsp90 inhibitor SNX‐2112 and prodrug SNX‐5422 (PF‐04929113) inhibit key signal pathways Akt, Src and STAT3 and reactivate tumor suppressor …
- Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
- … study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble Hsp90 inhibitor, 17-AAG, in …
- Abstract LB-289: Synthetic Hsp90 inhibitor, PF-04928473 and prodrug PF-04929113, demonstrates potent antitumor activity in head and neck cancer by inhibiting …
- Assessing the Impact of HER2 Status on the Antitumor Activity of an Hsp90 Inhibitor in Human Tumor Xenograft Mice using Pharmacokinetics-
Pharmacodynamic … - Preclinical Testing Demonstrates Striking Efficacy of STA-12-8666, an Hsp90 Inhibitor–Targeted SN-38 Conjugate, in Small Cell Lung Cancer: Small Cell Lung …
- Re: First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin Hsp90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
- Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells
- A novel Hsp90 inhibitor induces metabolic oxidative stress in head and neck squamous cancers and prevents migration and stem cell EMT even under hypoxic …
- Novel mechanism of attenuation of LPS-induced NF-κB activation by the Hsp90 inhibitor, 17-AAG, in human lung microvascular endothelial cells
- Supplemental Data Functional Characterization of the Biosynthesis of Radicicol, an Hsp90 Inhibitor Resorcylic Acid Lactone from Chaetomium chiversii
- The HALO study: A phase I-II of the oral Hsp90 inhibitor Debio0932 in combination with SOC in first-and second-line therapy of advanced NSCLC.
- Pharmacodynamic and clinical results from a phase 1/2 study of the Hsp90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer.
- AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo
- Abstract# 5443: Pharmacokinetics (PK) of PF-04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor after single and multiple dose …
- Hsp90 Inhibitor SNX-2112 Enhances TRAIL-Induced Apoptosis of Human Cervical Cancer Cells via the ROS-Mediated JNK-p53-Autophagy-DR5 Pathway
- A Phase IB Dose-Escalation Study of the Hsp90 Inhibitor SNX-5422 and Erlotinib in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to …
- Therapeutic Effects and Related Molecular Mechanisms of Celastrol, a Triterpenoid Natural Compound and Novel Hsp90 Inhibitor Extracted from Plants of the …
- Oral targeted delivery by nanoparticles enhances efficacy of an Hsp90 inhibitor by reducing systemic exposure in murine models of colitis and colitis-associated …
- Corrigendum to”” Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells””[Canc. Lett. 412 (2018) 297-307].
- Post-treatment with the heat shock protein 90 (Hsp90) inhibitor, 17-AAG, reduces pulmonary inflammation, hyper-permeability and airway dysfunction associated with …
- … Grevel A physiology-based model predicts pharmacokinetics, target occupancy in the tumour, and HSP70 biomarker response in serum for the Hsp90 inhibitor, 17 …
- An in vitro and in vivo evaluation of the combination of the heat shock protein 90 (Hsp90) inhibitor 17-allylamino, 17-demethoxygeldanamycin (17-AAG) and …
- Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high …
- EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the Hsp90 inhibitor ganetespib with carboplatin followed by …
- Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous …
- Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women …
- … 4-(4-(1-methyl-1H-pyrazol-4-
yl)-1H-imidazol-1-yl)-1H- pyrazolo[3,4-b]pyridin-1-yl) benzamide (TAS-116) as a Potent, Selective, and Orally Available Hsp90 Inhibitor - ET-44. HSP990-AN INHIBITOR OF Hsp90 CHAPERON PROTEIN TARGETS OLIG2-EXPRESSING GLIOMA STEM CELLS
- Targeting Hsp90 with the inhibitor AT13387 in tumour cells
- A novel Hsp90 machine inhibitor combining chemotherapy and immunotherapy
- Structural comparison of inhibitor binding to Hsp90 isoforms.
- TAS-116. Second-generation Hsp90-alpha/beta inhibitor, Cancer therapy
- A docking-based structural analysis of geldanamycin-derived inhibitor binding to human or Leishmania Hsp90
- Combination of Hsp90 and proteasome inhibitor is effective in pancreatic cancer
- Discovery of a synthetic small molecule inhibitor of Hsp90 for cancer therapy
- Study of the Binding Peptide-Derivatives on Hsp90 Protein which have Anti-Cancer and Autoimmune Inhibitor Effects
- Small Molecule Inhibitor for the Protein-Protein (Cdc37-Hsp90) Complex Studied by NMR
- Abstract# 4685: Identification of a potent and specific inhibitor of Hsp90 showing in vivo efficacy.
- Supplemental Data Structure-Activity Relationships in Purine-Based Inhibitor Binding to Hsp90 Isoforms
- Abstract# 5117: KU135, a novobiocin-derived C-terminal inhibitor of Hsp90, exerts potent antiproliferative effects in human leukemic Jurkat T cells
- Abstract# 2753: Biologic effects of NVP-AUY922, a novel small molecule inhibitor of Hsp90 in human colon and gastric cancer cell lines
- Glutaminyl cyclase inhibitor contributes to the regulation of HSP70, HSP90, actin, and ribosome on gene and protein levels in vitro
- Author Correction: Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations
- Abstract# LB-207: The antitumor effects of OSU-HDAC42, a histone deacetylase inhibitor, in HER2-positive breast cancer are mediated partly through Hsp90 …
- Abstract# 4684: NVP-BEP800/VER-82576: A potent orally active Hsp90 chaperone inhibitor evolved by SBDD from Vernalis fragment (\# 8220; SeeDs\# 8221;) hits …
- IPI-504, a selective inhibitor of Hsp90, exhibits potent anti-tumor activity against metastatic melanoma cell lines that harbor B-Raf or N-Ras mutations
- In Vitro Metabolism of 6-Chloro-9-(4-methoxy-3, 5-dimethylpyridin-2-ylmethyl)-
9H-purin-2-ylamine (BIIB021), an Inhibitor of HSP90, in Liver Microsomes and … - SIRT1 inhibitor 에 의한 Hsp90 inhibitor 의 Hsp90 샤페론 기능 억제 및 항암제 내성세포의 Hsp90 inhibitor 에 대한 세포독성 증강
- Radiosensitization of Hsp90 inhibitor Geldanamycin in normal and tumor cells.
- Hsp90 Inhibitor, 17-AAG, Affects Early Embryonic Development and Apoptosis of Bovine Embryos
- Discovery of FS36 as a novel Human Hsp90 inhibitor
- Novel Hsp90 Inhibitor Identified by Ligand-based Pharmacophore Modelx
- … of Hsp90 inhibitor in enhancing the anti-cancer effects of BCL-2 inhibitor in small cell lung cancer= 소세포폐암에서 BCL-2 억제제 항암효과를 향상시키는 Hsp90 …
- FW-04-806, a novel Hsp90 inhibitor, disrupt Hsp90/Cdc37 complex against human breast cancer cells
- The Hsp90 Inhibitor SY-J-55, Induces G2/M Arrest and Apoptosis in Paclitaxel-resistant Human Ovarian Cancer Cells
- Altered Cross Linking of HSP27 Sensitizes Breast Cancer Cells to Doxorubicin or Hsp90 inhibitor, 17-AAG
- GO-21: The Hsp90 Inhibitor SY-016, Induces G2/M Arrest and Apoptosis in Paclitaxel-resistant Human Ovarian Cancer Cells
- Hsp90 inhibitor, 17-AAG, abrogates breast cancer cells growth through EGFR and IGFR-1 pathway
- Novel Hsp90 inhibitor NVP-AUY922 downregulates mutant c-Kit protein through transcription and enhancing protein degradation via both proteasome and autophagy …
- Synergistic antitumor effect of Hsp90 inhibitor P7 combined with docetaxel in triple-negative breast cancer
- Synergistische Therapiewirkung der Kombination des Hsp90 Inhibitor AUY922 und des PI3K Inhibitors BYL719 mit Everolimus bei neuroendokrinen Tumoren
- Auy922, a novel Hsp90 inhibitor effective against ABC-dlbcl and malt lymphoma cells harboring genetic alteration-associated NF-kappa B activation
- 2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel Hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels
- Die Wirkung von Fumarsäure, intravenösen Immunglobulinen und dem Hsp90-Inhibitor 17-DMAG auf die Antikörper induzierte Leukozytenaktivierung im …
- … Untersuchungen zur Wirksamkeit des neuen Hsp90-Inhibitors AUY922 allein und in Kombination mit dem BCR-ABL-Inhibitor Imatinib zur Therapieoptimierung der …
- A heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate canser cell line …
- PP-646 非浸潤性膀胱癌に対する survivin-Hsp90 complex inhibitor 膀胱内注入療法モデルの確立 (発表・討論, 一般演題ポスター, 第 98 回日本泌尿器科学総会)
